US20110041195A1 - Organisms homozygous for targeted modification - Google Patents

Organisms homozygous for targeted modification Download PDF

Info

Publication number
US20110041195A1
US20110041195A1 US12/806,396 US80639610A US2011041195A1 US 20110041195 A1 US20110041195 A1 US 20110041195A1 US 80639610 A US80639610 A US 80639610A US 2011041195 A1 US2011041195 A1 US 2011041195A1
Authority
US
United States
Prior art keywords
sequence
reporter
cells
organism
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/806,396
Other languages
English (en)
Inventor
Yannick Doyon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sangamo Therapeutics Inc
Original Assignee
Sangamo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43586355&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20110041195(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sangamo Biosciences Inc filed Critical Sangamo Biosciences Inc
Priority to US12/806,396 priority Critical patent/US20110041195A1/en
Assigned to SANGAMO BIOSCIENCES, INC. reassignment SANGAMO BIOSCIENCES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DOYON, YANNICK
Publication of US20110041195A1 publication Critical patent/US20110041195A1/en
Priority to US13/066,636 priority patent/US20110247089A1/en
Priority to US13/828,218 priority patent/US20130198878A1/en
Priority to US15/990,176 priority patent/US10827731B2/en
Assigned to SANGAMO THERAPEUTICS, INC. reassignment SANGAMO THERAPEUTICS, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: SANGAMO BIOSCIENCES, INC.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/14—Plant cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
    • C12N15/8213—Targeted insertion of genes into the plant genome by homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)

Definitions

  • the present invention relates to organisms which are homozygous for targeted modification of one or more endogenous genes. More specifically, the invention concerns organisms (e.g., plants or animals) in which both alleles of a gene are disrupted but in which the homozygous knockout organism does not contain exogenous sequences at the disrupted locus. The invention also concerns organisms (e.g., plants or animals) in which both alleles of a gene are modified by insertion of a transgene, wherein the transgene lacks sequences encoding a reporter (e.g., selectable marker).
  • a reporter e.g., selectable marker
  • Organisms e.g., plants and animals
  • These organisms have traditionally been generated by inducing homologous recombination of a desired sequence (donor) at the gene selected for modification.
  • the targeting vector in order to select for cells which have the incorporated the donor DNA into the targeted locus, the targeting vector must include both positive and negative selection markers. See, e.g., U.S. Pat. No. 5,464,764.
  • the selected cells produce heterozygotes that must be crossed to obtain organisms homozygous for the gene modification.
  • the selection markers remain integrated in the organism's genome such that the resulting modified homozygote includes both the modified gene and exogenous (e.g., marker) sequences.
  • nucleases including zinc finger nucleases and homing endonucleases such as I-SceI, that are engineered to specifically bind to target sites have been successfully used for genome modification in a variety of different species. See, for example, United States Patent Publications 20030232410; 20050208489; 20050026157; 20050064474; 20060188987; 20060063231; 2008/0182332; 2009/0111188, and International Publication WO 07/014,275, the disclosures of which are incorporated by reference in their entireties for all purposes.
  • ZFNs can be used to create a double-strand break (DSB) in a target nucleotide sequence, which increases the frequency of donor nucleic acid introduction via homologous recombination at the targeted locus (targeted integration) more than 1000-fold.
  • NHEJ non-homologous end joining
  • an exogenous DNA including a selection marker or reporter gene is also targeted to the selected locus. See, e.g., Shukla et al. (2009) Nature 459(7245):437-441; U.S. Patent Publication Nos. 2008/0182332 and 2009/0111188. While targeted integration of a reporter allows for identification of modifications for a number of applications, this technique is not always desirable as it leaves additional exogenous nucleic acid sequences inserted into the genome.
  • compositions and methods for generating homozygous organisms modified at a desired gene locus including homozygous KO organisms without inserted exogenous sequences at, the locus (loci) targeted for modification and homozygous transgenic organisms without sequences encoding reporters such as selectable markers.
  • Described herein are homozygous organisms comprising a modification at a desired gene locus as well as methods and systems for generating these organisms.
  • Modified organisms include homozygous KO organisms without inserted exogenous sequences at the locus (loci) targeted for modification and homozygous transgenic organisms without sequences encoding reporters (e.g., selectable markers).
  • a modified organism comprising at least one gene locus in which both alleles of the locus are modified (e.g., disrupted), but wherein the modified organism does not comprise exogenous sequences at the modified locus.
  • the organisms as described herein may comprise one or more transgenes (exogenous sequences) at any locus that is not disrupted (knocked out).
  • a modified organism comprising at least one gene locus in which both alleles of the locus comprise a transgene, wherein the transgene does not comprise a reporter such as a screening or selectable marker.
  • a modified organism comprising at least one gene locus in which all alleles (e.g., in a tri- or tetraploid organism) of the locus comprise a transgene, wherein the transgene does not comprise a reporter such as a screening or selectable marker.
  • any of the organisms described herein may comprise more than one bi-allelic (or multi-allelic) modification (e.g., disruption or transgene).
  • the organism may be for example, a eukaryote (e.g., a plant or an animal such as a mammal, such as a rat, mouse, or fish).
  • a method of generating a homozygous (bi-allelic) knockout organism lacking exogenous sequences comprising, introducing an exogenous sequence (e.g., reporter) into a cell using a nuclease that mediates targeted integration of the exogenous sequence into a selected locus of the genome, identifying cells in which the exogenous sequence has been introduced into one allele of the target locus (mono-allelic TI cells), identifying mono-allelic TI cells comprising a NHEJ deletion at the other allele (TI/NHEJ clones), allowing the TI/NHEJ clones to develop to reproductive maturity, crossing the TI/NHEJ organisms to each other (or in the case of plants, also allowing the organism to “self”), and identifying progeny that exhibit bi-allelic NHEJ modifications, thereby generating a bi-allelic knockout organism lacking exogenous sequences at the target locus.
  • an exogenous sequence e.g., reporter
  • a method of generating a homozygous (bi-allelic) organism comprising desired transgene sequences lacking sequences encoding a reporter (e.g., selectable marker), the method comprising, introducing an exogenous reporter sequence into a cell using a nuclease that mediates targeted integration of the reporter exogenous sequence into a selected locus of the genome, introducing the desired transgene sequence(s) into a cell wherein the nuclease mediates targeted integration of the transgene sequence into the selected locus of the genome, identifying cells in which the exogenous reporter sequence has been introduced into one allele of the target locus (mono-allelic reporter-TI cells), identifying mono-allelic reporter-TI cells comprising a transgene insertion at the other allele (reporter-TI/transgene clones), allowing the reporter-TI/transgene clones to develop to reproductive maturity, crossing the reporter-TI/transgene organisms to each other (or in the case
  • the nuclease comprises one or more zinc finger nucleases (ZFN). In other embodiments, the nuclease comprises a homing endonuclease or meganuclease, or a TAL-effector domain nuclease fusion (“TALEN”).
  • the exogenous sequence e.g., exogenous reporter sequence
  • transgene may be introduced concurrently or sequentially with the nuclease(s).
  • the exogenous sequence comprises a reporter gene such as a selectable marker (e.g., an herbicide resistant gene for plants) or a screening marker (e.g. a fluorescent protein).
  • any of the methods described herein may be repeated to generate organisms that are homozygous KOs or contain homozygous transgene insertions at multiple loci. It will be apparent that any of the methods described herein can be applied to polyploid organisms (e.g., by repeating the steps) that include more than two alleles, for example, tri- or tetraploid plants.
  • kits that are useful for generating organisms with homozygous targeted gene modifications without inserted reporter (e.g screening or selection) sequences.
  • the kits typically include one or more nucleases (or polynucleotides encoding the nuclease) that bind to a target site (the selected locus for modification), optional cells containing the target site(s) of the nuclease, an exogenous sequence for targeted integration, an optional donor transgene comprising sequences homologous to the target site, and instructions for (i) introducing the nucleases and exogenous sequence into the cells; (ii) identifying cells into which the exogenous sequences are inserted into an allele at the target locus; (iii) identifying cells having mono-allelic targeted integration of the exogenous reporter sequence and modifications at the other allele of the locus (reporter-TI/modified cells); (iv) growing/developing selected cells into reproductively mature organisms; (v) crossing the reporter-TI/modified heterozyg
  • FIG. 1 depicts sequence analysis of the non-TI allele of a ZFN-TI-modified IPK1 chromatid from Zea mays .
  • Underlined base pairs show the binding sites for ZFN pair used for genomic modifications.
  • the “:” indicate deleted bases.
  • the wild-type sequence is indicated in the first line and the multiple sequence reads of the sequenced non-TI allele event are shown below.
  • FIG. 2 depicts the scheme for introducing a fluorescent protein (enhanced yellow fluorescent protein (EYFP)) into the 3′ untranslated region of the murine histone H3.3B gene.
  • the top line shows the schematic of the H3.3B gene in the murine genome on chromosome 11 and shows the target site on the gene sequence for the H3.3B-specific ZFN.
  • the second line depicts the donor nucleotide (“targeting construct”) comprising a H3.3B gene linked to a EYFP sequence where the EYFP has been inserted at the 5′ end of the 3′ untranslated region.
  • the bottom line depicts the insertion of the donor nucleotide into the H3.3B locus in the murine genome.
  • FIG. 3 depicts the results from FACS and Southern blot analysis demonstrating the heterozygous integration of the EYFP transgene into murine ES cells.
  • FIG. 3A depicts the FACS results of ES cells lacking the inserted EYFP gene sequence in the H3.3B locus (top panel) and those results for cells that received the H3.3B-EYFP insertion.
  • FIG. 3B depicts a Southern blot derived from genomic DNA of cells that have the inserted H3.3B-EYFP sequence versus wildtype cells.
  • FIG. 4 depicts the sequences from 19 non-reporter alleles demonstrating NHEJ in the H3.3B-EYFP/heterozygotes. Underlined base pairs show the binding sites for the ZFN pair used for the modifications. The “-” indicate deleted bases or spaces in the sequence to allow for alignment with the clones containing insertions.
  • Described herein are homozygously modified organisms, including knockout (KO) organisms with no added genetic material at either allele of targeted locus and knock-in organisms that include transgenes of interest, but in which the transgene of interest lacks sequences encoding a reporter such as selectable marker. Also described are methods of generating these modified organisms. In particular, the organisms typically have modifications that alter gene function at both alleles.
  • These organisms are generated by providing cells from the organism of interest, using nucleases to insert an exogenous reporter sequence (e.g., screening or selectable marker) via targeted integration (TI) into an allele at a selected locus in the cell, identifying cells in which the exogenous reporter sequence was inserted into an allele at the selected locus, screening the mono-allelic reporter-TI clones for modification events at the second allele of the locus to identify cells with one reporter TI allele and in which the other allele is modified by NHEJ (reporter TI/NHEJ) or in which the other allele comprises a non-reporter marker transgene (reporter-TI/modified clones), allowing the reporter-TI/modified clones to develop to reproductively mature organisms, crossing the reporter-TI/modified organisms, and identifying progeny of the crosses that are biallelic knockout (NHEJ/NHEJ) or biallelic non-reporter marker knock-in (non-reporter TI/n
  • MOLECULAR CLONING A LABORATORY MANUAL, Second edition, Cold Spring Harbor Laboratory Press, 1989 and Third edition, 2001; Ausubel et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, 1987 and periodic updates; the series METHODS IN ENZYMOLOGY, Academic Press, San Diego; Wolffe, CHROMATIN STRUCTURE AND FUNCTION, Third edition, Academic Press, San Diego, 1998; METHODS IN ENZYMOLOGY, Vol. 304, “Chromatin” (P.M. Wassarman and A. P.
  • nucleic acid refers to a deoxyribonucleotide or ribonucleotide polymer, in linear or circular conformation, and in either single- or double-stranded form.
  • polynucleotide refers to a deoxyribonucleotide or ribonucleotide polymer, in linear or circular conformation, and in either single- or double-stranded form.
  • these terms are not to be construed as limiting with respect to the length of a polymer.
  • the terms can encompass known analogues of natural nucleotides, as well as nucleotides that are modified in the base, sugar and/or phosphate moieties (e.g., phosphorothioate backbones).
  • an analogue of a particular nucleotide has the same base-pairing specificity; i.e., an analogue of A will base-pair with T.
  • polypeptide “peptide” and “protein” are used interchangeably to refer to a polymer of amino acid residues.
  • the term also applies to amino acid polymers in which one or more amino acids are chemical analogues or modified derivatives of corresponding naturally-occurring amino acids.
  • Binding refers to a sequence-specific, non-covalent interaction between macromolecules (e.g., between a protein and a nucleic acid). Not all components of a binding interaction need be sequence-specific (e.g., contacts with phosphate residues in a DNA backbone), as long as the interaction as a whole is sequence-specific. Such interactions are generally characterized by a dissociation constant (K d ) of 10 ⁇ 6 M ⁇ 1 or lower. “Affinity” refers to the strength of binding: increased binding affinity being correlated with a lower K d .
  • a “binding protein” is a protein that is able to bind non-covalently to another molecule.
  • a binding protein can bind to, for example, a DNA molecule (a DNA-binding protein), an RNA molecule (an RNA-binding protein) and/or a protein molecule (a protein-binding protein).
  • a DNA-binding protein a DNA-binding protein
  • an RNA-binding protein an RNA-binding protein
  • a protein-binding protein it can bind to itself (to form homodimers, homotrimers, etc.) and/or it can bind to one or more molecules of a different protein or proteins.
  • a binding protein can have more than one type of binding activity. For example, zinc finger proteins have DNA-binding, RNA-binding and protein-binding activity.
  • a “TAL-effector DNA binding domain” is a protein, or a domain within a larger protein, that interacts with DNA in a sequence-specific manner through one or more tandem repeat domains.
  • a “zinc finger DNA binding protein” (or binding domain) is a protein, or a domain within a larger protein, that binds DNA in a sequence-specific manner through one or more zinc fingers, which are regions of amino acid sequence within the binding domain whose structure is stabilized through coordination of a zinc ion.
  • the term zinc finger DNA binding protein is often abbreviated as zinc finger protein or ZFP.
  • Zinc finger binding domains can be “engineered” to bind to a predetermined nucleotide sequence.
  • the engineered region of the zinc finger is typically the recognition helix, particularly the portion of the alpha-helical region numbered ⁇ 1 to +6.
  • Backbone sequences for an engineered recognition helix are known in the art. See, e.g., Miller et al. (2007) Nat Biotechnol 25, 778-785.
  • Non-limiting examples of methods for engineering zinc finger proteins are design and selection.
  • a designed zinc finger protein is a protein not occurring in nature whose design/composition results principally from rational criteria.
  • Rational criteria for design include application of substitution rules and computerized algorithms for processing information in a database storing information of existing ZFP designs and binding data. See, for example, U.S. Pat. Nos. 6,140,081; 6,453,242; and 6,534,261; see, also WO 98/53058; WO 98/53059; WO 98/53060; WO 02/016536 and WO 03/016496.
  • a “selected” zinc finger protein is a protein not found in nature whose production results primarily from an empirical process such as phage display, interaction trap or hybrid selection. See e.g., U.S. Pat. Nos. 5,789,538; 5,925,523; 6,007,988; 6,013,453; 6,200,759; and International Patent Publication Nos. WO 95/19431; WO 96/06166; WO 98/53057; WO 98/54311; WO 00/27878; WO 01/60970; WO 01/88197 and WO 02/099084.
  • sequence refers to a nucleotide sequence of any length, which can be DNA or RNA; can be linear, circular or branched and can be either single-stranded or double stranded.
  • donor sequence refers to a nucleotide sequence that is inserted into a genome.
  • a donor sequence can be of any length, for example between 2 and 10,000 nucleotides in length (or any integer value therebetween or thereabove), preferably between about 100 and 1,000 nucleotides in length (or any integer therebetween), more preferably between about 200 and 500 nucleotides in length.
  • a “homologous, non-identical sequence” refers to a first sequence which shares a degree of sequence identity with a second sequence, but whose sequence is not identical to that of the second sequence.
  • a polynucleotide comprising the wild-type sequence of a mutant gene is homologous and non-identical to the sequence of the mutant gene.
  • the degree of homology between the two sequences is sufficient to allow homologous recombination therebetween, utilizing normal cellular mechanisms.
  • Two homologous non-identical sequences can be any length and their degree of non-homology can be as small as a single, nucleotide (e.g., for correction of a genomic point mutation by targeted homologous recombination) or as large as 10 or more kilobases (e.g., for insertion of a gene at a predetermined ectopic site in a chromosome).
  • Two polynucleotides comprising the homologous non-identical sequences need not be the same length.
  • an exogenous polynucleotide i.e., donor polynucleotide
  • an exogenous polynucleotide i.e., donor polynucleotide of between 20 and 10,000 nucleotides or nucleotide pairs can be used.
  • nucleic acid and amino acid sequence identity are known in the art. Typically, such techniques include determining the nucleotide sequence of the mRNA for a gene and/or determining the amino acid sequence encoded thereby, and comparing these sequences to a second nucleotide or amino acid sequence. Genomic sequences can also be determined and compared in this fashion. In general, identity refers to an exact nucleotide-to-nucleotide or amino acid-to-amino acid correspondence of two polynucleotides or polypeptide sequences, respectively. Two or more sequences (polynucleotide or amino acid) can be compared by determining their percent identity. The percent identity of two sequences, whether nucleic acid or amino acid sequences, is the number of exact matches between two aligned sequences divided by the length of the shorter sequences and multiplied by 100.
  • the degree of sequence similarity between polynucleotides can be determined by hybridization of polynucleotides under conditions that allow formation of stable duplexes between homologous regions, followed by digestion with single-stranded-specific nuclease(s), and size determination of the digested fragments.
  • Two nucleic acid, or two polypeptide sequences are substantially homologous to each other when the sequences exhibit at least about 70%-75%, preferably 80%-82%, more preferably 85%-90%, even more preferably 92%, still more preferably 95%, and most preferably 98% sequence identity over a defined length of the molecules, as determined using the methods above.
  • substantially homologous also refers to sequences showing complete identity to a specified DNA or polypeptide sequence.
  • DNA sequences that are substantially homologous can be identified in a Southern hybridization experiment under, for example, stringent conditions, as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art. See, e.g., Sambrook et al., supra; Nucleic Acid Hybridization: A Practical Approach , editors B. D. Hames and S. J. Higgins, (1985) Oxford; Washington, D.C.; IRL Press).
  • “Recombination” refers to a process of exchange of genetic information between two polynucleotides.
  • “homologous recombination (HR)” refers to the specialized form of such exchange that takes place, for example, during repair of double-strand breaks in cells via homology-directed repair mechanisms. This process requires nucleotide sequence homology, uses a “donor” molecule to template repair of a “target” molecule (i.e., the one that experienced the double-strand break), and is variously known as “non-crossover gene conversion” or “short tract gene conversion,” because it leads to the transfer of genetic information from the donor to the target.
  • such transfer can involve mismatch correction of heteroduplex DNA that forms between the broken target and the donor, and/or “synthesis-dependent strand annealing,” in which the donor is used to resynthesize genetic information that will become part of the target, and/or related processes.
  • Such specialized HR often results in an alteration of the sequence of the target molecule such that part or all of the sequence of the donor polynucleotide is incorporated into the target polynucleotide.
  • one or more targeted nucleases as described herein create a double-stranded break in the target sequence (e.g., cellular chromatin) at a predetermined site, and a “donor” polynucleotide, having homology to the nucleotide sequence in the region of the break, can be introduced into the cell.
  • a “donor” polynucleotide having homology to the nucleotide sequence in the region of the break
  • the presence of the double-stranded break (DSB) has been shown to facilitate integration of the donor sequence.
  • the donor sequence may be physically integrated or, alternatively, the donor polynucleotide is used as a template for repair of the break via homologous recombination, resulting in the introduction of all or part of the nucleotide sequence as in the donor into the cellular chromatin.
  • a first sequence in cellular chromatin can be altered and, in certain embodiments, can be converted into a sequence present in a donor polynucleotide.
  • the use of the terms “replace” or “replacement” can be understood to represent replacement of one nucleotide sequence by another, (i.e., replacement of a sequence in the informational sense), and does not necessarily require physical or chemical replacement of one polynucleotide by another.
  • two DSBs are introduced by the targeted nucleases described herein, resulting in the deletion of the DNA in between the DSBs.
  • the “donor” polynucleotides are inserted between these two DSBs.
  • portions of the donor sequence that are homologous to sequences in the region of interest exhibit between about 80 to 99% (or any integer therebetween) sequence identity to the genomic sequence that is replaced.
  • the homology between the donor and genomic sequence is higher than 99%, for example if only 1 nucleotide differs as between donor and genomic sequences of over 100 contiguous base pairs.
  • a non-homologous portion of the donor sequence can contain sequences not present in the region of interest, such that new sequences are introduced into the region of interest.
  • the non-homologous sequence is generally flanked by sequences of 50-1,000 base pairs (or any integral value therebetween) or any number of base pairs greater than 1,000, that are homologous or identical to sequences in the region of interest.
  • the donor sequence is non-homologous to the first sequence, and is inserted into the genome by non-homologous recombination mechanisms.
  • Any of the methods described herein can be used for partial or complete inactivation of one or more target sequences in a cell by targeted integration of donor sequence that disrupts expression of the gene(s) of interest.
  • Cell lines with partially or completely inactivated genes are also provided.
  • the methods of targeted integration as described herein can also be used to integrate one or more exogenous sequences.
  • the exogenous nucleic acid sequence can comprise, for example, one or more genes or cDNA molecules, or any type of coding or noncoding sequence, as well as one or more control elements (e.g., promoters).
  • the exogenous nucleic acid sequence may produce one or more RNA molecules (e.g., small hairpin RNAs (shRNAs), inhibitory RNAs (RNAis), microRNAs (miRNAs), etc.).
  • “Cleavage” refers to the breakage of the covalent backbone of a DNA molecule. Cleavage can be initiated by a variety of methods including, but not limited to, enzymatic or chemical hydrolysis of a phosphodiester bond. Both single-stranded cleavage and double-stranded cleavage are possible, and double-stranded cleavage can occur as a result of two distinct single-stranded cleavage events. DNA cleavage can result in the production of either blunt ends or staggered ends. In certain embodiments, fusion polypeptides are used for targeted double-stranded DNA cleavage.
  • a “cleavage half-domain” is a polypeptide sequence which, in conjunction with a second polypeptide (either identical or different) forms a complex having cleavage activity (preferably double-strand cleavage activity).
  • first and second cleavage half-domains;” “+ and ⁇ cleavage half-domains” and “right and left cleavage half-domains” are used interchangeably to refer to pairs of cleavage half-domains that dimerize.
  • An “engineered cleavage half-domain” is a cleavage half-domain that has been modified so as to form obligate heterodimers with another cleavage half-domain (e.g., another engineered cleavage half-domain). See, also, U.S. Patent Publication Nos. 2005/0064474, 20070218528 and 2008/0131962, incorporated herein by reference in their entireties.
  • Chromatin is the nucleoprotein structure comprising the cellular genome.
  • Cellular chromatin comprises nucleic acid, primarily DNA, and protein, including histones and non-histone chromosomal proteins.
  • the majority of eukaryotic cellular chromatin exists in the form of nucleosomes, wherein a nucleosome core comprises approximately 150 base pairs of DNA associated with an octamer comprising two each of histones H2A, H2B, H3 and H4; and linker DNA (of variable length depending on the organism) extends between nucleosome cores.
  • a molecule of histone H1 is generally associated with the linker DNA.
  • chromatin is meant to encompass all types of cellular nucleoprotein, both prokaryotic and eukaryotic.
  • Cellular chromatin includes both chromosomal and episomal chromatin.
  • a “chromosome,” is a chromatin complex comprising all or a portion of the genome of a cell.
  • the genome of a cell is often characterized by its karyotype, which is the collection of all the chromosomes that comprise the genome of the cell.
  • the genome of a cell can comprise one or more chromosomes.
  • an “episome” is a replicating nucleic acid, nucleoprotein complex or other structure comprising a nucleic acid that is not part of the chromosomal karyotype of a cell.
  • Examples of episomes include plasmids and certain viral genomes.
  • a “target site” or “target sequence” is a nucleic acid sequence that defines a portion of a nucleic acid to which a binding molecule will bind, provided sufficient conditions for binding exist.
  • the sequence 5′-GAATTC-3′ is a target site for the Eco RI restriction endonuclease.
  • exogenous molecule is a molecule that is not normally present in a cell, but can be introduced into a cell by one or more genetic, biochemical or other methods. “Normal presence in the cell” is determined with respect to the particular developmental stage and environmental conditions of the cell. Thus, for example, a molecule that is present only during embryonic development of muscle is an exogenous molecule with respect to an adult muscle cell. Similarly, a molecule induced by heat shock is an exogenous molecule with respect to a non-heat-shocked cell.
  • An exogenous molecule can comprise, for example, a functioning version of a malfunctioning endogenous molecule or a malfunctioning version of a normally-functioning endogenous molecule.
  • An exogenous molecule can be, among other things, a small molecule, such as is generated by a combinatorial chemistry process, or a macromolecule such as a protein, nucleic acid, carbohydrate, lipid, glycoprotein, lipoprotein, polysaccharide, any modified derivative of the above molecules, or any complex comprising one or more of the above molecules.
  • Nucleic acids include DNA and RNA, can be single- or double-stranded; can be linear, branched or circular; and can be of any length. Nucleic acids include those capable of forming duplexes, as well as triplex-forming nucleic acids. See, for example, U.S. Pat. Nos. 5,176,996 and 5,422,251.
  • Proteins include, but are not limited to, DNA-binding proteins, transcription factors, chromatin remodeling factors, methylated DNA binding proteins, polymerases, methylases, demethylases, acetylases, deacetylases, kinases, phosphatases, integrases, recombinases, ligases, topoisomerases, gyrases and helicases.
  • exogenous molecule can be the same type of molecule as an endogenous molecule, e.g., an exogenous protein or nucleic acid.
  • an exogenous nucleic acid can comprise an infecting viral genome, a plasmid or episome introduced into a cell, or a chromosome that is not normally present in the cell.
  • Methods for the introduction of exogenous molecules into cells include, but are not limited to, lipid-mediated transfer (i.e., liposomes, including neutral and cationic lipids), electroporation, direct injection, cell fusion, particle bombardment, calcium phosphate co-precipitation, DEAE-dextran-mediated transfer and viral vector-mediated transfer.
  • an “endogenous” molecule is one that is normally present in a particular cell at a particular developmental stage under particular environmental conditions.
  • an endogenous nucleic acid can comprise a chromosome, the genome of a mitochondrion, chloroplast or other organelle, or a naturally-occurring episomal nucleic acid.
  • Additional endogenous molecules can include proteins, for example, transcription factors and enzymes.
  • a “fusion” molecule is a molecule in which two or more subunit molecules are linked, preferably covalently.
  • the subunit molecules can be the same chemical type of molecule, or can be different chemical types of molecules.
  • Examples of the first type of fusion molecule include, but are not limited to, fusion proteins (for example, a fusion between a ZFP DNA-binding domain and a cleavage domain or between a TAL-effector DNA binding domain and a cleavage domain) and fusion nucleic acids (for example, a nucleic acid encoding the fusion protein described supra).
  • Examples of the second type of fusion molecule include, but are not limited to, a fusion between a triplex-forming nucleic acid and a polypeptide, and a fusion between a minor groove binder and a nucleic acid.
  • Fusion protein in a cell can result from delivery of the fusion protein to the cell or by delivery of a polynucleotide encoding the fusion protein to a cell, wherein the polynucleotide is transcribed, and the transcript is translated, to generate the fusion protein.
  • Trans-splicing, polypeptide cleavage and polypeptide ligation can also be involved in expression of a protein in a cell. Methods for polynucleotide and polypeptide delivery to cells are presented elsewhere in this disclosure.
  • Gene expression refers to the conversion of the information, contained in a gene, into a gene product.
  • a gene product can be the direct transcriptional product of a gene (e.g., mRNA, tRNA, rRNA, antisense RNA, ribozyme, structural RNA, shRNA, RNAi, miRNA or any other type of RNA) or a protein produced by translation of a mRNA.
  • Gene products also include RNAs which are modified, by processes such as capping, polyadenylation, methylation, and editing, and proteins modified by, for example, methylation, acetylation, phosphorylation, ubiquitination, ADP-ribosylation, myristilation, and glycosylation.
  • Modulation of gene expression refers to a change in the activity of a gene. Modulation of expression can include, but is not limited to, gene activation and gene repression. Genome editing (e.g., cleavage, alteration, inactivation, donor integration, random mutation) can be used to modulate expression. Gene inactivation refers to any reduction in gene expression as compared to a cell that does not include a modifier as described herein. Thus, gene inactivation may be partial or complete.
  • a “region of interest” is any region of cellular chromatin, such as, for example, a gene or a non-coding sequence within or adjacent to a gene, in which it is desirable to bind an exogenous molecule. Binding can be for the purposes of targeted DNA cleavage and/or targeted recombination.
  • a region of interest can be present in a chromosome, an episome, an organellar genome (e.g., mitochondrial, chloroplast), or an infecting viral genome, for example.
  • a region of interest can be within the coding region of a gene, within transcribed non-coding regions such as, for example, leader sequences, trailer sequences or introns, or within non-transcribed regions, either upstream or downstream of the coding region.
  • a region of interest can be as small as a single nucleotide pair or up to 2,000 nucleotide pairs in length, or any integral value of nucleotide pairs.
  • Eukaryotic cells include, but are not limited to, fungal cells (such as yeast), plant cells, animal cells, mammalian cells and human cells (e.g., T-cells).
  • Plant cells include, but are not limited to, cells of monocotyledonous (monocots) or dicotyledonous (dicots) plants.
  • monocots include cereal plants such as maize, rice, barley, oats, wheat, sorghum, rye, sugarcane, pineapple, onion, banana, and coconut.
  • dicots include tobacco, tomato, sunflower, cotton, sugarbeet, potato, lettuce, melon, soybean, canola (rapeseed), and alfalfa.
  • Plant cells may be from any part of the plant and/or from any stage of plant development.
  • operative linkage and “operatively linked” (or “operably linked”) are used interchangeably with reference to a juxtaposition of two or more components (such as sequence elements), in which the components are arranged such that both components function normally and allow the possibility that at least one of the components can mediate a function that is exerted upon at least one of the other components.
  • a transcriptional regulatory sequence such as a promoter
  • a transcriptional regulatory sequence is generally operatively linked in cis with a coding sequence, but need not be directly adjacent to it.
  • an enhancer is a transcriptional regulatory sequence that is operatively linked to a coding sequence, even though they are not contiguous.
  • the term “operatively linked” can refer to the fact that each of the components performs the same function in linkage to the other component as it would if it were not so linked.
  • the ZFP DNA-binding domain and the cleavage domain are in operative linkage if, in the fusion polypeptide, the ZFP DNA-binding domain portion is able to bind its target site and/or its binding site, while the cleavage domain is able to cleave DNA in the vicinity of the target site.
  • a “functional fragment” of a protein, polypeptide or nucleic acid is a protein, polypeptide or nucleic acid whose sequence is not identical to the full-length protein, polypeptide or nucleic acid, yet retains the same function as the full-length protein, polypeptide or nucleic acid.
  • a functional fragment can possess more, fewer, or the same number of residues as the corresponding native molecule, and/or can contain one or more amino acid or nucleotide substitutions.
  • DNA-binding function of a polypeptide can be determined, for example, by filter-binding, electrophoretic mobility-shift, or immunoprecipitation assays. DNA cleavage can be assayed by gel electrophoresis. See Ausubel et al., supra.
  • the ability of a protein to interact with another protein can be determined, for example, by co-immunoprecipitation, two-hybrid assays or complementation, both genetic and biochemical. See, for example, Fields et al. (1989) Nature 340:245-246; U.S. Pat. No. 5,585,245 and PCT WO 98/44350.
  • a “vector” is capable of transferring gene sequences to target cells.
  • vector construct means any nucleic acid construct capable of directing the expression of a gene of interest and which can transfer gene sequences to target cells.
  • vector transfer vector mean any nucleic acid construct capable of directing the expression of a gene of interest and which can transfer gene sequences to target cells.
  • the term includes cloning, and expression vehicles, as well as integrating vectors.
  • reporter gene refers to any sequence that produces a protein product that is easily measured, preferably in a routine assay.
  • Suitable reporter genes for particular species will be known to the skilled artisan and include, but are not limited to, Mel1, chloramphenicol acetyl transferase (CAT), light generating proteins such as GFP, luciferase and/or ⁇ -galactosidase.
  • CAT chloramphenicol acetyl transferase
  • Suitable reporter genes for animals may also encode markers or enzymes that can be measured in vivo such as thymidine kinase, measured in vivo using PET scanning, or luciferase, measured in vivo via whole body luminometric imaging.
  • Positive selection markers are those polynucleotides that encode a product that enables only cells that carry and express the gene to survive and/or grow under certain conditions. For example, cells that express neomycin resistance (Neo r ) gene are resistant to the compound G418, while cells that do not express Neo r are skilled by G418. Likewise, plant cells that express an herbicide tolerance (resistance) gene (e.g., PAT (phosphinothricin acetyl transferase) gene), which confers resistance to the herbicide bialaphos. Other examples of positive selection markers including hygromycin resistance and the like will be known to those of skill in the art.
  • PAT phosphinothricin acetyl transferase
  • Negative selection markers are those polynucleotides that encode a product that enables only cells that carry and express the gene to be killed under certain conditions. For example, cells that express thymidine kinase (e.g., herpes simplex virus thymidine kinase, HSV-TK) are killed when gancyclovir is added. Other negative selection markers are known to those skilled in the art.
  • the selectable marker need not be a transgene and, additionally, reporters and selectable markers can be used in various combinations.
  • compositions and methods for generating homozygously modified, including knock-out (KO) organisms without inserted exogenous sequences such as selectable markers and organisms containing a transgene without sequences encoding reporters (e.g., selectable markers) at both alleles of the desired locus are typically generated in two steps.
  • one or more nucleases e.g., ZFNs
  • TI targeted integration
  • the heterologous sequence typically contains a reporter (e.g., selectable or screening marker) that allows for selection of clones with a reporter-TI at one allele of the locus of interest.
  • a desired transgene donor (lacking reporter sequences) is co-introduced with the reporter donor.
  • the reporter-TI-selected clones are then genotyped at the non-reporter-TI allele to identify cells in which the non-reporter-TI allele is disrupted by NHEJ, or to identify cells that contain the non-reporter marker transgene inserted at the non-reporter-TI allele.
  • the reporter-TI/modified clones e.g., reporter-TI/NHEJ or reporter-TI/non-reporter TI clones identified as above are allowed to develop to reproductive maturity and then these reporter-TI/modified heterozygous organisms are crossed to each other or self crossed.
  • One-quarter of the progeny of the reporter-TI/modified organisms from these crosses are expected to be homozygous for the modified events (NHEJ/NHEJ or non-reporter TI/non-reporter TI), thus providing homozygously modified organisms without any inserted reporter DNA.
  • nucleases include meganucleases, zinc finger nucleases and TALENs.
  • the nuclease may comprise heterologous DNA-binding and cleavage domains (e.g., zinc finger nucleases; meganuclease DNA-binding domains with heterologous cleavage domains or TALENs) or, alternatively, the DNA-binding domain of a naturally-occurring nuclease may be altered to bind to a selected target site (e.g., a meganuclease that has been engineered to bind to site different than the cognate binding site).
  • a selected target site e.g., a meganuclease that has been engineered to bind to site different than the cognate binding site.
  • the nuclease is a meganuclease (homing endonuclease).
  • Naturally-occurring meganucleases recognize 15-40 base-pair cleavage sites and are commonly grouped into four families: the LAGLIDADG family, the GIY-YIG family, the His-Cyst box family and the HNH family.
  • Exemplary homing endonucleases include I-SceI, I-CeuI, PI-PspI, PI-Sce, I-SceIV, I-CsmI, I-PanI, I-SceII, I-PpoI, I-SceIII, I-CreI, I-TevI, I-TevII and I-TevIII.
  • Their recognition sequences are known. See also U.S. Pat. No. 5,420,032; U.S. Pat. No. 6,833,252; Belfort et al. (1997) Nucleic Acids Res. 25:3379-3388; Dujon et al.
  • DNA-binding domains from naturally-occurring meganucleases primarily from the LAGLIDADG family, have been used to promote site-specific genome modification in plants, yeast, Drosophila , mammalian cells and mice, but this approach has been limited to the modification of either homologous genes that conserve the meganuclease recognition sequence (Monet et al. (1999), Biochem. Biophysics. Res. Common. 255: 88-93) or to pre-engineered genomes into which a recognition sequence has been introduced (Route et al. (1994), Mol. Cell. Biol. 14: 8096-106; Chilton et al. (2003), Plant Physiology. 133: 956-65; Puchta et al.
  • TAL transcription activator-like effectors
  • AvrBs3 from Xanthomonas campestgris pv.
  • TAL-effectors contain a centralized domain of tandem repeats, each repeat containing approximately 34 amino acids, which are key to the DNA binding specificity of these proteins. In addition, they contain a nuclear localization sequence and an acidic transcriptional activation domain (for a review see Schornack S, et al (2006) J Plant Physiol 163(3): 256-272).
  • Ralstonia solanacearum two genes, designated brg11 and hpx17 have been found that are homologous to the AvrBs3 family of Xanthomonas in the R.
  • solanacearum biovar 1 strain GMI1000 and in the biovar 4 strain RS1000 See Heuer et al (2007) Appl and Envir Micro 73(13): 4379-4384).
  • These genes are 98.9% identical in nucleotide sequence to each other but differ by a deletion of 1,575 bp in the repeat domain of hpx17.
  • both gene products have less than 40% sequence identity with AvrBs3 family proteins of Xanthomonas.
  • TAL effectors depends on the sequences found in the tandem repeats.
  • the repeated sequence comprises approximately 102 bp and the repeats are typically 91-100% homologous with each other (Bonas et al, ibid).
  • Polymorphism of the repeats is usually located at positions 12 and 13 and there appears to be a one-to-one correspondence between the identity of the hypervariable diresidues at positions 12 and 13 with the identity of the contiguous nucleotides in the TAL-effector's target sequence (see Moscou and Bogdanove, (2009) Science 326:1501 and Boch et al (2009) Science 326:1509-1512).
  • the code for DNA recognition of these TAL-effectors has been determined such that an HD sequence at positions 12 and 13 leads to a binding to cytosine (C), NG binds to T, NI to A, C, G or T, NN binds to A or G, and IG binds to T.
  • C cytosine
  • NG binds to T
  • NI to A
  • C G or T
  • NN binds to A or G
  • IG binds to T.
  • These DNA binding repeats have been assembled into proteins with new combinations and numbers of repeats, to make artificial transcription factors that are able to interact with new sequences and activate the expression of a reporter gene in plant cells (Boch et al, ibid).
  • these DNA binding domains have not been shown to have general applicability in the field of targeted genomic editing or targeted gene regulation in all cell types.
  • Boch et al showed function in plant cells only (namely, in the biological setting for which these domains have evolved to function in) and did not demonstrate activity at an endogenous locus.
  • engineered TAL-effectors have not been shown to function in association with any exogenous functional protein effector domains (nuclease, transcription factor, regulatory, enzymatic, recombinase, methylase, and/or reporter domains) not naturally found in natural Xanthomonas TAL-effector proteins in mammalian cells.
  • any exogenous functional protein effector domains nuclease, transcription factor, regulatory, enzymatic, recombinase, methylase, and/or reporter domains
  • engineered TAL proteins were linked to a FokI cleavage half domain to yield a TAL effector domain nuclease fusion (TALEN) and were shown to be active in a yeast reporter assay where cleavage of the plasmid based target is require for the assay.
  • TALEN TAL effector domain nuclease fusion
  • the nuclease is a zinc finger nuclease (ZFN).
  • ZFNs comprise a zinc finger protein that has been engineered to bind to a target site in a gene of, choice and cleavage domain or a cleavage half-domain.
  • Zinc finger binding domains can be engineered to bind to a sequence of choice. See, for example, Beerli et al. (2002) Nature Biotechnol. 20:135-141; Pabo et al. (2001) Ann. Rev. Biochem. 70:313-340; Isalan et al. (2001) Nature Biotechnol. 19:656-660; Segal et al. (2001) Curr. Opin. Biotechnol. 12:632-637; Choo et al. (2000) Curr. Opin. Struct. Biol. 10:411-416.
  • An engineered zinc finger binding domain can have a novel binding specificity, compared to a naturally-occurring zinc finger protein.
  • Rational design include's, for example, using databases comprising triplet (or quadruplet) nucleotide sequences and individual zinc finger amino acid sequences, in which each triplet or quadruplet nucleotide sequence is associated with one or more amino acid sequences of zinc fingers which bind the particular triplet or quadruplet sequence. See, for example, co-owned U.S. Pat. Nos. 6,453,242 and 6,534,261, incorporated by reference herein in their entireties.
  • Exemplary selection methods including phage display and two-hybrid systems, are disclosed in U.S. Pat. Nos. 5,789,538; 5,925,523; 6,007,988; 6,013,453; 6,410,248; 6,140,466; 6,200,759; and 6,242,568; as well as WO 98/37186; WO 98/53057; WO 00/27878; WO 01/88197 and GB 2,338,237.
  • enhancement of binding specificity for zinc finger binding domains has been described, for example, in co-owned WO 02/077227.
  • zinc finger domains and/or multi-fingered zinc finger proteins may be linked together using any suitable linker sequences, including for example, linkers of 5 or more amino acids in length. See, e.g., U.S. Pat. Nos. 6,479,626; 6,903,185; and 7,153,949 for exemplary linker sequences 6 or more amino acids in length.
  • the proteins described herein may include any combination of suitable linkers between the individual zinc fingers of the protein.
  • Nucleases such as ZFNs, TALENs and/or meganucleases also comprise a nuclease (cleavage domain, cleavage half-domain).
  • the cleavage domain may be heterologous to the DNA-binding domain, for example a zinc finger DNA-binding domain and a cleavage domain from a nuclease or a meganuclease DNA-binding domain or a TAL-effector domain and a cleavage domain from a different nuclease.
  • Heterologous cleavage domains can be obtained from any endonuclease or exonuclease.
  • Exemplary endonucleases from which a cleavage domain can be derived include, but are not limited to, restriction endonucleases and homing endonucleases. See, for example, 2002-2003 Catalogue, New England Biolabs, Beverly, Mass.; and Belfort et al. (1997) Nucleic Acids Res. 25:3379-3388. Additional enzymes which cleave DNA are known (e.g., S1 Nuclease; mung bean nuclease; pancreatic DNase I; micrococcal nuclease; yeast HO endonuclease; see also Linn et al. (eds.) Nucleases , Cold Spring Harbor Laboratory Press, 1993). One or more of these enzymes (or functional fragments thereof) can be used as a source of cleavage domains and cleavage half-domains.
  • a cleavage half-domain can be derived from any nuclease or portion thereof, as set forth above, that requires dimerization for cleavage activity.
  • two fusion proteins are required for cleavage if the fusion proteins comprise cleavage half-domains.
  • a single protein comprising two cleavage half-domains can be used.
  • the two cleavage half-domains can be derived from the same endonuclease (or functional fragments thereof), or each cleavage half-domain can be derived from a different endonuclease (or functional fragments thereof).
  • the target sites for the two fusion proteins are preferably disposed, with respect to each other, such that binding of the two fusion proteins to their respective target sites places the cleavage half-domains in a spatial orientation to each other that allows the cleavage half-domains to form a functional cleavage domain, e.g., by dimerizing.
  • the near edges of the target sites are separated by 5-8 nucleotides or by 15-18 nucleotides.
  • any integral number of nucleotides or nucleotide pairs can intervene between two target sites (e.g., from 2 to 50 nucleotide pairs or more).
  • the site of cleavage lies between the target sites.
  • Restriction endonucleases are present in many species and are capable of sequence-specific binding to DNA (at a recognition site), and cleaving DNA at or near the site of binding.
  • Certain restriction enzymes e.g., Type IIS
  • Fok I catalyzes double-stranded cleavage of DNA, at 9 nucleotides from its recognition site on one strand and 13 nucleotides from its recognition site on the other. See, for example, U.S. Pat. Nos. 5,356,802; 5,436,150 and 5,487,994; as well as Li et al.
  • fusion proteins comprise the cleavage domain (or cleavage half-domain) from at least one Type IIS restriction enzyme and one or more zinc finger binding domains, which may or may not be engineered.
  • Fok I An exemplary Type IIS restriction enzyme, whose cleavage domain is separable from the binding domain, is Fok I.
  • This particular enzyme is active as a dimer. Bitinaite et al. (1998) Proc. Natl. Acad. Sci. USA 95: 10,570-10,575. Accordingly, for the purposes of the present disclosure, the portion of the Fok I enzyme used in the disclosed fusion proteins is considered a cleavage half-domain.
  • two fusion proteins, each comprising a FokI cleavage half-domain can be used to reconstitute a catalytically active cleavage domain.
  • a single polypeptide molecule containing a zinc finger binding domain and two Fok I cleavage half-domains can also be used. Parameters for targeted cleavage and targeted sequence alteration using zinc finger-Fok I fusions are provided elsewhere in this disclosure.
  • a cleavage domain or cleavage half-domain can be any portion of a protein that retains cleavage activity, or that retains the ability to multimerize (e.g., dimerize) to form a functional cleavage domain.
  • Type IIS restriction enzymes are described in International Publication WO 07/014,275, incorporated herein in its entirety. Additional restriction enzymes also contain separable binding and cleavage domains, and these are contemplated by the present disclosure. See, for example, Roberts et al. (2003) Nucleic Acids Res. 31:418-420.
  • the cleavage domain comprises one or more engineered cleavage half-domain (also referred to as dimerization domain mutants) that minimize or prevent homodimerization, as described, for example, in U.S. Patent Publication Nos. 20050064474 and 20060188987 and in U.S. application Ser. No. 11/805,850 (filed May 23, 2007), the disclosures of all of which are incorporated by reference in their entireties herein.
  • engineered cleavage half-domain also referred to as dimerization domain mutants
  • Exemplary engineered cleavage half-domains of Fok I that form obligate heterodimers include a pair in which a first cleavage half-domain includes mutations at amino acid residues at positions 490 and 538 of Fok I and a second cleavage half-domain includes mutations at amino acid residues 486 and 499.
  • a mutation at 490 replaces Glu (E) with Lys (K); the mutation at 538 replaces Iso (I) with Lys (K); the mutation at 486 replaced Gln (Q) with Glu (E); and the mutation at position 499 replaces Iso (I) with Lys (K).
  • the engineered cleavage half-domains described herein were prepared by mutating positions 490 (E ⁇ K) and 538 (I ⁇ K) in one cleavage half-domain to produce an engineered cleavage half-domain designated “E490K:I538K” and by mutating positions 486 (Q ⁇ E) and 499 (I ⁇ L) in another cleavage half-domain to produce an engineered cleavage half-domain designated “Q486E:I499L”.
  • the engineered cleavage half-domains described herein are obligate heterodimer mutants in which aberrant cleavage is minimized or abolished. See, e.g., U.S. Patent Publication No. 2008/0131962, the disclosure of which is incorporated by reference in its entirety for all purposes.
  • the engineered cleavage half-domains described herein are obligate heterodimer mutants in which aberrant cleavage is minimized or abolished. See, e.g., Example 1 of WO 07/139,898.
  • the engineered cleavage half-domain comprises mutations at positions 486, 499 and 496 (numbered relative to wild-type FokI), for instance mutations that replace the wild type Gln (Q) residue at position 486 with a Glu (E) residue, the wild type Iso (I) residue at position 499 with a Leu (L) residue and the wild-type Asn (N) residue at position 496 with an Asp (D) or Glu (E) residue (also referred to as a “ELD” and “ELE” domains, respectively).
  • the engineered cleavage half-domain comprises mutations at positions 490, 538 and 537 (numbered relative to wild-type FokI), for instance mutations that replace the wild type Glu (E) residue at position 490 with a Lys (K) residue, the wild type Iso (I) residue at position 538 with a Lys (K) residue, and the wild-type His (H) residue at position 537 with a Lys (K) residue or a Arg (R) residue (also referred to as “KKK” and “KKR” domains, respectively).
  • the engineered cleavage half-domain comprises mutations at positions 490 and 537 (numbered relative to wild-type FokI), for instance mutations that replace the wild type Glu (E) residue at position 490 with a Lys (K) residue and the wild-type His (H) residue at position 537 with a Lys (K) residue or a Arg (R) residue (also referred to as “KIK” and “KIR” domains, respectively).
  • E wild type Glu
  • K Lys
  • H His
  • R Arg
  • Engineered cleavage half-domains described herein can be prepared using any suitable method, for example, by site-directed mutagenesis of wild-type cleavage half-domains (Fok I) as described in U.S. Patent Publication Nos. 20050064474 and 20080131962.
  • nucleases may be assembled in vivo at the nucleic acid target site using so-called “split-enzyme” technology (see e.g. U.S. Patent Publication No. 20090068164).
  • split-enzyme e.g. U.S. Patent Publication No. 20090068164.
  • Components of such split enzymes may be expressed either on separate expression constructs, or can be linked in one open reading frame where the individual components are separated, for example, by a self-cleaving 2A peptide or IRES sequence.
  • Components may be individual zinc finger binding domains or domains of a meganuclease nucleic acid binding domain.
  • Nucleases e.g., ZFNs
  • ZFNs yeast-based chromosomal system as described in WO 2009/042163 and 20090068164.
  • a nucleic acid encoding one or more nucleases can be cloned into a vector for transformation into prokaryotic or eukaryotic cells.
  • Vectors can be prokaryotic vectors, e.g., plasmids, or shuttle vectors, insect vectors, or eukaryotic vectors, including plant vectors described herein.
  • Nuclease expression constructs can be readily designed using methods known in the art. See, e.g., United States Patent Publications 20030232410; 20050208489; 20050026157; 20050064474; 20060188987; 20060063231; 20080182332; 2009011188 and International Publication WO 07/014,275.
  • Expression of the nuclease may be under the control of a constitutive promoter or an inducible promoter, for example the galactokinase promoter which is activated (de-repressed) in the presence of raffinose and/or galactose and repressed in presence of glucose.
  • plant promoters include promoter sequences derived from A.
  • ubi-3 thaliana ubiquitin-3 (ubi-3) (Callis, et al., 1990 , J. Biol. Chem. 265-12486-12493); A. tumifaciens mannopine synthase ( ⁇ mas) (Petolino et al., U.S. Pat. No. 6,730,824); and/or Cassava Vein Mosaic Virus (CsVMV) (Verdaguer et al., (1996) Plant Molecular Biology 31:1129-1139). Additional suitable bacterial and eukaryotic promoters are well known in the art and described, e.g., in Sambrook et al., Molecular Cloning, A Laboratory Manual (2nd ed.
  • the expression vector typically contains a transcription unit or expression cassette that contains all the additional elements required for the expression of the nucleic acid in host cells, either prokaryotic or eukaryotic.
  • a typical expression cassette thus contains a promoter operably linked, e.g., to a nucleic acid sequence encoding the nuclease, and signals required, e.g., for efficient polyadenylation of the transcript, transcriptional termination, ribosome binding sites, or translation termination.
  • Additional elements of the cassette may include, e.g., enhancers, heterologous splicing signals, and/or a nuclear localization signal (NLS).
  • Kits for such expression systems are commercially available.
  • Eukaryotic expression systems for mammalian cells, yeast, plant and insect cells are well known by those of skill in the art and are also commercially available.
  • Any of the well known procedures for introducing foreign nucleotide sequences into such host cells may be used. These include the use of calcium phosphate transfection, polybrene, protoplast fusion, electroporation, ultrasonic methods (e.g., sonoporation), liposomes, microinjection, naked DNA, plasmid vectors, viral vectors, both episomal and integrative, and any of the other well known methods for introducing cloned genomic DNA, cDNA, synthetic DNA or other foreign genetic material into a host cell (see, e.g., Sambrook et al., supra). It is only necessary that the particular genetic engineering procedure used be capable of successfully introducing at least one gene into the host cell capable of expressing the protein of choice.
  • DNA constructs may be introduced into (e.g., into the genome of) a desired plant host by a variety of conventional techniques.
  • Conventional techniques see, for example, Weissbach & Weissbach Methods for Plant Molecular Biology (1988, Academic Press, N.Y.) Section VIII, pp. 421-463; and Grierson & Corey, Plant Molecular Biology (1988, 2d Ed.), Blackie, London, Ch. 7-9.
  • the DNA construct may be introduced directly into the genomic DNA of the plant cell using techniques such as electroporation and microinjection of plant cell protoplasts, or the DNA constructs can be introduced directly to plant tissue using biolistic methods, such as DNA particle bombardment (see, e.g., Klein et al (1987) Nature 327:70-73).
  • the DNA constructs may be combined with suitable T-DNA flanking regions and introduced into a conventional Agrobacterium tumefaciens host vector.
  • Agrobacterium tumefaciens -mediated transformation techniques, including disarming and use of binary vectors, are well described in the scientific literature. See, for example Horsch et al (1984) Science 233:496-498, and Fraley et al (1983) Proc. Natl. Acad. Sci. USA 80:4803.
  • gene transfer may be achieved using non-Agrobacterium bacteria or viruses such as Rhizobium sp. NGR234 , Sinorhizoboium meliloti, Mesorhizobium loti , potato virus X, cauliflower mosaic virus and cassava vein mosaic virus and/or tobacco mosaic virus, See, e.g., Chung et al. (2006) Trends Plant Sci. 11(1):1-4.
  • non-Agrobacterium bacteria or viruses such as Rhizobium sp. NGR234 , Sinorhizoboium meliloti, Mesorhizobium loti , potato virus X, cauliflower mosaic virus and cassava vein mosaic virus and/or tobacco mosaic virus, See, e.g., Chung et al. (2006) Trends Plant Sci. 11(1):1-4.
  • the virulence functions of the Agrobacterium tumefaciens host will direct the insertion of the construct and adjacent marker into the plant cell DNA when the cell is infected by the bacteria using binary T DNA vector (Bevan (1984) Nuc. Acid Res. 12:8711-8721) or the co-cultivation procedure (Horsch et al (1985) Science 227:1229-1231).
  • binary T DNA vector Bevan (1984) Nuc. Acid Res. 12:8711-8721
  • the co-cultivation procedure Horsch et al (1985) Science 227:1229-1231.
  • the Agrobacterium transformation system is used to engineer dicotyledonous plants (Bevan et al (1982) Ann. Rev. Genet. 16:357-384; Rogers et al (1986) Methods Enzymol. 118:627-641).
  • the Agrobacterium transformation system may also be used to transform, as well as transfer, DNA to monocotyledonous plants and plant cells. See U.S. Pat. No. 5,591,616; Hernalsteen et al (1984) EMBO J. 3:3039-3041; Hooykass-Van Slogteren et al (1984) Nature 311:763-764; Grimsley et al (1987) Nature 325:1677-179; Boulton et al (1989) Plant Mol. Biol. 12:31-40; and Gould et al (1991) Plant Physiol. 95:426-434.
  • Alternative gene transfer and transformation methods include, but are not limited to, protoplast transformation through calcium-, polyethylene glycol (PEG)- or electroporation-mediated uptake of naked DNA (see Paszkowski et al. (1984) EMBO J. 3:2717-2722, Potrykus et al. (1985) Molec. Gen. Genet. 199:169-177; Fromm et al. (1985) Proc. Nat. Acad. Sci. USA 82:5824-5828; and Shimamoto (1989) Nature 338:274-276) and electroporation of plant tissues (D'Halluin et al. (1992) Plant Cell 4:1495-1505).
  • PEG polyethylene glycol
  • Additional methods for plant cell transformation include microinjection, silicon carbide mediated DNA uptake (Kaeppler et al. (1990) Plant Cell Reporter 9:415-418), and microprojectile bombardment (see Klein et al. (1988) Proc. Nat. Acad. Sci. USA 85:4305-4309; and Gordon-Kamm et al. (1990) Plant Cell 2:603-618).
  • nucleases are administered in any suitable manner, preferably with pharmaceutically acceptable carriers. Suitable methods of administering such modulators are available and well known to those of skill in the art, and, although more than one route can be used to administer a particular composition, a particular route can often provide a more immediate and more effective reaction than another route.
  • Carriers may also be used and are determined in part by the particular composition being administered, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions that are available (see, e.g., Remington's Pharmaceutical Sciences, 17 th ed. 1985).
  • the present invention is applicable to any organism in which it is desired to create a homozygously modified organism, including but not limited to eukaryotic organisms such as plants, animals (e.g., mammals such as mice, rats, primates, farm animals, rabbits, etc.), fish, and the like.
  • eukaryotic organisms such as plants, animals (e.g., mammals such as mice, rats, primates, farm animals, rabbits, etc.), fish, and the like.
  • the organisms are generated using isolated cells from the organism that can be genetically modified as described herein and can develop into reproductively mature organisms.
  • Eukaryotic e.g., yeast, plant, fungal, piscine and mammalian cells such as feline, canine, murine, bovine, and porcine
  • Cells from organisms containing one or more homozygous KO loci as described herein or other genetic modifications can also be used.
  • Exemplary mammalian cells include any cell or cell line of the organism of interest, for example oocytes, K562 cells, CHO (Chinese hamster ovary) cells, HEP-G2 cells, BaF-3 cells, Schneider cells, COS cells (monkey kidney cells expressing SV40 T-antigen), CV-1 cells, HuTu80 cells, NTERA2 cells, NB4 cells, HL-60 cells and HeLa cells, 293 cells (see, e.g., Graham et al. (1977) J. Gen. Virol. 36:59), and myeloma cells like SP2 or NS0 (see, e.g., Galfre and Milstein (1981) Meth. Enzymol. 73(B):3 46).
  • oocytes K562 cells
  • CHO (Chinese hamster ovary) cells HEP-G2 cells
  • BaF-3 cells BaF-3 cells
  • Schneider cells COS cells (monkey kidney cells expressing SV40 T-antigen)
  • PBMCs Peripheral blood mononucleocytes
  • T-cells can also be used, as can embryonic and adult stem cells.
  • stem cells that can be used include embryonic stem cells (ES), induced pluripotent stem cells (iPSC), mesenchymal stem cells, hematopoietic stem cells, muscle stem cells, skin stem cells and neuronal stem cells.
  • ES embryonic stem cells
  • iPSC induced pluripotent stem cells
  • mesenchymal stem cells mesenchymal stem cells
  • hematopoietic stem cells muscle stem cells
  • skin stem cells and neuronal stem cells.
  • Exemplary target plants and plant cells include, but are not limited to, those monocotyledonous and dicotyledonous plants, such as crops including grain crops (e.g., wheat, maize, rice, millet, barley), fruit crops (e.g., tomato, apple, pear, strawberry, orange), forage crops (e.g., alfalfa), root vegetable crops (e.g., carrot, potato, sugar beets, yam), leafy vegetable crops (e.g., lettuce, spinach); flowering plants (e.g., petunia, rose, chrysanthemum), conifers and pine trees (e.g., pine fir, spruce); plants used in phytoremediation (e.g., heavy metal accumulating plants); oil crops (e.g., sunflower, rape seed) and plants used for experimental purposes (e.g., Arabidopsis ).
  • crops including grain crops (e.g., wheat, maize, rice, millet, barley), fruit
  • the disclosed methods and compositions have use over a broad range of plants, including, but not limited to, species from the genera Asparagus, Avena, Brassica, Citrus, Citrullus, Capsicum, Cucurbita, Daucus, Erigeron, Glycine, Gossypium, Hordeum, Lactuca, Lolium, Lycopersicon, Malus, Manihot, Nicotiana, Orychophragmus, Oryza, Persea, Phaseolus, Pisum, Pyrus, Prunus, Raphanus, Secale, Solanum, Sorghum, Triticum, Vitis, Vigna , and Zea .
  • plant cells include isolated plant cells as well as whole plants or portions of whole plants such as seeds, callus, leaves, roots, etc.
  • the present disclosure also encompasses seeds of the plants described above wherein the seed has the transgene or gene construct.
  • the present disclosure further encompasses the progeny, clones, cell lines or cells of the transgenic plants described above wherein said progeny, clone, cell line or cell has the transgene or gene construct.
  • the first step in generating homozygously modified organisms as described herein involves nuclease-mediated targeted integration of a donor (exogenous) reporter sequence at the desired target locus.
  • the disclosed nucleases can be used to cleave DNA at a region of interest in cellular chromatin (e.g., at a desired or predetermined site in a genome).
  • the DNA binding domain of a nuclease e.g., zinc finger binding domain
  • a fusion protein comprising the DNA binding domain and a cleavage domain is expressed in a cell.
  • the DNA-binding domain e.g., zinc finger portion
  • two fusion proteins each comprising a zinc finger binding domain and a cleavage half-domain, are expressed in a cell, and bind to target sites which are juxtaposed in such a way that a functional cleavage domain is reconstituted and DNA is cleaved in the vicinity of the target sites.
  • cleavage occurs between the target sites of the two zinc finger binding domains.
  • One or both of the zinc finger binding domains can be engineered.
  • Targeted cleavage by nucleases as described herein has been shown to result in targeted integration of a donor (exogenous) sequence (via homology-directed repair) at the site of cleavage. See, e.g., U.S. Patent Publication Nos. 2007/0134796, 2008/029580, 2008/0182332, 2009/0117617, and 2009/0111188.
  • targeted replacement (integration) of a selected genomic sequence also requires the introduction of the replacement (or donor) reporter sequence.
  • the donor reporter sequence can be introduced into the cell prior to, concurrently with, or subsequent to, expression of the fusion protein(s).
  • the donor reporter polynucleotide generally contains sufficient homology to a genomic sequence to support homologous recombination (or homology-directed repair) between it and the genomic sequence to which it bears homology. It will be readily apparent that the donor sequences are typically not identical to the genomic sequence that they replace.
  • the sequence of the donor polynucleotides can contain one or more single base changes, insertions, deletions, inversions or rearrangements with respect to the genomic sequence, so long as sufficient homology with chromosomal sequences is present.
  • introduction of a desired transgene may also be accomplished.
  • the desired transgene donor sequences will also have sufficient homology to the genomic sequence to support homologous recombination or homology-directed repair between it and the genomic sequence to which it has homology. See, e.g., U.S. patent application Ser. No. 12/386,059.
  • Donor transgenes of interest typically contain sequences encoding a sequence of interest. Non-limiting examples include gene regulator sequences (e.g. promoter sequences), sequences encoding a protein product (e.g. proteins involved in phenotypic modification of the organism or a therapeutic protein) or sequences encoding a RNA product such as a shRNA, RNAi etc.
  • the donor reporter sequence typically includes a sequence encoding a reporter gene for identification of cells in which targeted integration has occurred. Any reporter gene can be used.
  • the reporter gene provides a directly detectable signal directly, for example, a signal from a fluorescent protein such as, for example, GFP (green fluorescent protein). Fluorescence is detected using a variety of commercially available fluorescent detection systems, including, e.g., a fluorescence-activated cell sorter (FACS) system.
  • FACS fluorescence-activated cell sorter
  • Reporter genes may also be enzymes that catalyze the production of a detectable product (e.g. proteases, nucleases; lipases, phosphatases, sugar hydrolases and esterases).
  • a detectable product e.g. proteases, nucleases; lipases, phosphatases, sugar hydrolases and esterases.
  • suitable reporter genes that encode enzymes include, for example, MEL1, CAT (chloramphenicol acetyl transferase; Alton and Vapnek (1979) Nature 282:864 869), luciferase, ⁇ -galactosidase, ⁇ -glucuronidase, ⁇ -lactamase, horseradish peroxidase and alkaline phosphatase (e.g., Toh, et al. (1980) Eur. J. Biochem. 182:231238; and Hall et al. (1983) J. Mol. Appl. Gen. 2:101).
  • Additional reporter genes include selectable markers (e.g., positive and/or negative selection markers), including but not limited to antibiotic resistance such as ampicillin resistance, neomycin resistance, G418 resistance, puromycin resistance as well as herbicide resistance such a PAT gene.
  • selectable markers e.g., positive and/or negative selection markers
  • antibiotic resistance such as ampicillin resistance, neomycin resistance, G418 resistance, puromycin resistance as well as herbicide resistance such a PAT gene.
  • the donor polynucleotides can be DNA or RNA, single-stranded or double-stranded and can be introduced into a cell in linear or circular, form. If introduced in linear form, the ends of the donor sequence can be protected (e.g., from exonucleolytic degradation) by methods known to those of skill in the art. For example, one or more dideoxynucleotide residues are added to the 3′ terminus of a linear molecule and/or self-complementary oligonucleotides are ligated to one or both ends. See, for example, Chang et al. (1987) Proc. Natl. Acad. Sci.
  • Additional methods for protecting exogenous polynucleotides from degradation include, but are not limited to, addition of terminal amino group(s) and the use of modified internucleotide linkages such as, for example, phosphorothioates, phosphoramidates, and O-methyl ribose or deoxyribose residues.
  • a polynucleotide can be introduced into a cell as part of a vector molecule having additional sequences such as, for example, replication origins, promoters and genes encoding antibiotic or herbicide resistance.
  • donor polynucleotides can be introduced as naked nucleic acid, as nucleic acid complexed with an agent such as a liposome or poloxamer, or can be delivered by viruses (e.g., adenovirus, AAV, herpesvirus, retrovirus, lentivirus).
  • viruses e.g., adenovirus, AAV, herpesvirus, retrovirus, lentivirus.
  • Cells can be assayed for targeted integration in any suitable way, including by examination (sequencing or PCR) or the selected locus or by selecting and/or screening the treated cells for traits encoded by the marker genes present on the donor DNA. For instance, selection may be performed by growing the engineered cells on media containing an inhibitory amount of the antibiotic or herbicide to which the transforming gene construct confers resistance. Further, transformed cells may also be identified by screening for the activities of any visible marker genes (e.g., fluorescent proteins, ⁇ -glucuronidase, luciferase, B or C1 genes) that may be present on the recombinant nucleic acid constructs. Such selection and screening methodologies are well known to those skilled in the art.
  • visible marker genes e.g., fluorescent proteins, ⁇ -glucuronidase, luciferase, B or C1 genes
  • Physical and biochemical methods also may be used to identify cells containing the donor sequences inserted into the targeted locus. These methods include but are not limited to: 1) Southern analysis or PCR amplification for detecting and determining the structure of the recombinant DNA insert; 2) Northern blot, S1 RNase protection, primer-extension or reverse transcriptase-PCR amplification for detecting and examining RNA transcripts of the gene constructs; 3) enzymatic assays for detecting enzyme or ribozyme activity, where such gene products are encoded by the gene construct; 4) protein gel electrophoresis, Western blot techniques, immunoprecipitation, or enzyme-linked immunoassays, where the gene construct products are proteins.
  • RNA e.g., mRNA
  • Effects of gene manipulation using the methods disclosed herein can be observed by, for example, northern blots of the RNA (e.g., mRNA) isolated from the tissues of interest. Typically, if the amount of mRNA has increased, it can be assumed that the corresponding endogenous gene is being expressed at a greater rate than before. Other methods of measuring gene and/or CYP74B activity can be used. Different types of enzymatic assays can be used, depending on the substrate used and the method of detecting the increase or decrease of a reaction product or by-product.
  • the levels of and/or CYP74B protein expressed can be measured immunochemically, i.e., ELISA, RIA, EIA and other antibody based assays well known to those of skill in the art, such as by electrophoretic detection assays (either with staining or western blotting).
  • reporter-TI/modified cells can be identified using any suitable method known to the skilled artisan, including sequencing, PCR analysis and the like.
  • the reporter-TI/modified mutants are cultured or otherwise treated such that they generate a whole organism with reporter-TI/modified genotype at the desired locus.
  • traditional methods of pro-nuclear injection or oocyte injection can be used to generate reporter-TI/modified animals. See, e.g., U.S. Patent Application No. 61/205,970 showing germline transmission of ZFN-modified rat oocytes.
  • reporter-TI/modified plant cells can be cultured to regenerate a whole plant which possesses the transformed genotype and thus the desired phenotype.
  • Such regeneration techniques rely on manipulation of certain phytohormones in a tissue culture growth medium, typically relying on a biocide and/or herbicide marker which has been introduced together with the desired nucleotide sequences. Plant regeneration from cultured protoplasts is described in Evans, et al., “Protoplasts Isolation and Culture” in Handbook of Plant Cell Culture, pp. 124-176, Macmillian Publishing Company, New York, 1983; and Binding, Regeneration of Plants, Plant Protoplasts , pp. 21-73, CRC Press, Boca Raton, 1985.
  • Regeneration can also be obtained from plant callus, explants, organs, pollens, embryos or parts thereof. Such regeneration techniques are described generally in Klee et al (1987) Ann. Rev. of Plant Phys. 38:467-486.
  • One of skill in the art will recognize that after the expression cassette is stably incorporated in transgenic plants and confirmed to be operable, it can be introduced into other plants by sexual crossing. Any of a number of standard breeding techniques can be used, depending upon the species to be crossed. Further still, haploid organisms (e.g. gametophytes) may be created following meiosis of the transgenic organism. There are several organisms such as algae, fungi and some plants that are able to live at least part of their lifecycle in a haploid state.
  • the reporter TI/modified heterozygous organisms can be crossed to each other, or in some instances, spores may be grown into haploids. Of the resulting progeny from crosses, approximately 25% will be homozygous modified/modified (NHEJ/NHEJ or non-reporter TI/non-reporter TI) at the target locus. Half of the haploid offspring will contain the modification of interest.
  • the modified/modified organisms can be identified using any of the methods described above, including, but not limited to sequencing, PCR analysis and the like. These organisms will have the desired homozygous gene modification, but will not include any inserted exogenous reporter sequences (e.g., markers).
  • kits for generating organisms typically contain polynucleotides encoding one or more nucleases and/or donor polynucleotides (e.g., with selectable markers) as described herein as well as instructions for analyzing selected TI clones for modifications at the non-reporter-TI allele and instructions for crossing the reporter-TI/modified organisms to each other to generate organisms that are homozygous at the disrupted locus without any inserted donor DNA into which the nucleases and/or donor polynucleotide are introduced.
  • the kits can also contain cells, reagents, buffers for transformation of cells, culture media for cells, and/or buffers for performing assays.
  • the kits also contain a label which includes any material such as instructions, packaging or advertising leaflet that is attached to or otherwise accompanies the other components of the kit.
  • the homozygously modified organisms described herein can be used for any application in which KO organisms with inserted exogenous sequences are currently used. Such organisms find use in biological and medical research, production of pharmaceutical drugs, experimental medicine, and agriculture.
  • KO animals have proved very useful in analyzing the function of gene products and creating models for human diseases, thereby allowing drug discovery.
  • KO plants as described herein can be used to create crops with the desired genes disrupted but without the inserted sequences that potentially could damage native crops.
  • KO plants as described herein can be non-transgenic GMOs in the sense that they do not include exogenous DNA.
  • the KO organisms can lack inserted sequences at the disrupted locus (loci) but include transgenes at another locus or loci.
  • Creating plants or animals that are homozygous for a transgene but lack a exogenous reporter sequence is often desirable.
  • methods and compositions described herein provide tools for generation of plants and animals in which a desired (non-reporter) gene sequence has been inserted into both alleles but the resultant plant progeny do not contain any reporter sequences.
  • regulator sequences may be inserted to control (repress or activate) a specific gene of interest.
  • a transgene may be inserted into all the alleles of a locus of interest. The transgene may be inserted to knock out a particular gene where expression of the target gene is not desired.
  • nuclease comprises a zinc finger nuclease (ZFN).
  • ZFN zinc finger nuclease
  • ZFNs targeted to the IPK1 gene in Zea mays were used for targeted insertion (TI) of a herbicide resistant gene (PAT).
  • TI targeted insertion
  • PAT herbicide resistant gene
  • the ZFNs used and TI techniques are described in Shukla et al. (2009) Nature 459:437-441 and U.S. Patent Publication Nos. 20080182332 and 20090111188.
  • ZFNs precisely modified the target locus by mono-allelic or bi-allelic targeted integration of the selectable marker.
  • TI/-(mono-allelic) clones were genotyped at the non-TI allele.
  • an event of the events sequenced at the non-TI allele had a NHEJ-induced mutation (deletion) at the non-TI allele.
  • FIG. 1 shows the wild type sequence and multiple sequence reads of the event. Such events are designated TI/NHEJ.
  • TI/NHEJ events are then self pollinated by standard methods to obtain plants are that are bi-allelic knockouts ( ⁇ / ⁇ or NHEJ/NHEJ) at the targeted locus, but are devoid of the inserted reporter (selectable marker) sequence.
  • ZFNs targeted to the murine histone H3.3B were used for targeted integration of a fluorescent marker enhanced yellow fluorescent protein (EYFP) at the start of the 3′ untranslated portion of this gene.
  • EYFP enhanced yellow fluorescent protein
  • the ZFNs were constructed essentially as described in U.S. Pat. No. 6,534,261.
  • the recognition helices for the ZFN pair used as well as the target sequence are shown below in Tables 1 and 2.
  • Target Site 7269 cgCCGGATACGGGGag (SEQ ID NO: 9) 7270 gcCAACTGGATGTCtt (SEQ ID NO: 10)
  • a donor DNA was constructed containing the H3.3B gene operably linked to the EYFP sequence (see FIG. 2 ). Briefly, a PCR fragment of genomic DNA from mouse H3.3B was cloned out of a genomic bacterial artificial chromosome (BAC) from C57BL/6J mouse chromosome 11 using Phusion polymerase (NEB F-530L) and into a pCR2.1 vector (pCR2.1-H3.3B) using TA-TOPO cloning (Invitrogen K4500-02).
  • BAC genomic bacterial artificial chromosome
  • NEB F-530L Phusion polymerase
  • pCR2.1-H3.3B pCR2.1-H3.3B
  • H3.3B-EYFP donor construct pCR2.1-H3.3B-EYFP
  • the H3.3B-EYFP donor included no H3.3B promoter sequence, containing approximately 0.6 kb of 5′ homologous genomic sequence starting at the second H3.3B codon, including introns, until the last H3.3B coding amino acid, followed by the linker and EYFP, a stop codon, and approximately 1.3 kb homologous to the H3.3B 3′UTR.
  • mice ES cells were transfected by Amaxa nucleofection.
  • ES cells were feeder depleted by harvesting the ES cells, plating on a feeder-free dish for 30 min, and then collecting the ES enriched non-adherent cells for transfection.
  • ES cells were resuspended in 90 ⁇ l solution, mixed with two non-linearized plasmids (1 ⁇ g of ZFN plasmid with both ZFNs separated by a 2A peptide sequence+10 ⁇ g of donor plasmid) in 10 ⁇ l nucleofection solution, and transfected using program A-013 as described in the Amaxa manufacturer's protocol for mouse ES cells.
  • ES cells were cultured in standard conditions on treated feeders for 3-5 days prior to fluorescent activated cell sorting (FACS) or fluorescent colony picking. Following colony picking, clonal isolation and expansion, genomic DNA was prepared using the Qiagen DNeasy Blood & Tissue Kit (Qiagen 69504). Individual clones were screened by PCR. PCR products from both wild-type and modified H3.3B alleles were sequenced using standard methods.
  • genomic DNA was digested from wild-type and targeted ES cells with BsrBI, and used a labeled 638 bp AvaII fragment of the H3.3B donor as probe to visualize wild-type H3.3B and integrated H3.3B donors.
  • the stem cells containing the heterozygous reporter TI/modified alleles at the locus of interest are used to generate homozygous modified/modified mice using standard protocols (for example see Manipulating the Mouse Embryo, A Laboratory Manual, 3 rd Edition Nagy et al, eds. Cold Spring Harbor Laboratory Press (2003)).
  • Heterozygous cells are generated wherein one allele of the PPP1R12C gene (see U.S. Patent Publication No. 20080299580) contains the PGK-GFP-pA selectable marker, and the other allele contains a transgene carrying a novel RFLP in the PPP1R12C gene that creates a Hind III restriction site.
  • K562 cells are transfected with the ZFN expression plasmids as described above along with the two donor molecules.
  • One donor comprises the reporter GFP driven by the PGK promoter, and the other donor comprises a PPP1R12C gene with the novel RFLP.
  • GFP positive cells are isolated by limiting dilution and visual inspection. Clones are grown up and genomic DNA is isolated for genotyping by PCR and sequencing.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Environmental Sciences (AREA)
  • Cell Biology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Enzymes And Modification Thereof (AREA)
US12/806,396 2009-08-11 2010-08-11 Organisms homozygous for targeted modification Abandoned US20110041195A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US12/806,396 US20110041195A1 (en) 2009-08-11 2010-08-11 Organisms homozygous for targeted modification
US13/066,636 US20110247089A1 (en) 2009-08-11 2011-04-20 Organisms homozygous for targeted modification
US13/828,218 US20130198878A1 (en) 2009-08-11 2013-03-14 Organisms homozygous for targeted modification
US15/990,176 US10827731B2 (en) 2009-08-11 2018-05-25 Method of inactivating the IPK1 gene in corn

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27392809P 2009-08-11 2009-08-11
US12/806,396 US20110041195A1 (en) 2009-08-11 2010-08-11 Organisms homozygous for targeted modification

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US13/068,735 Continuation-In-Part US8586526B2 (en) 2009-08-11 2011-05-17 DNA-binding proteins and uses thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/066,636 Continuation US20110247089A1 (en) 2009-08-11 2011-04-20 Organisms homozygous for targeted modification
US15/990,176 Continuation US10827731B2 (en) 2009-08-11 2018-05-25 Method of inactivating the IPK1 gene in corn

Publications (1)

Publication Number Publication Date
US20110041195A1 true US20110041195A1 (en) 2011-02-17

Family

ID=43586355

Family Applications (4)

Application Number Title Priority Date Filing Date
US12/806,396 Abandoned US20110041195A1 (en) 2009-08-11 2010-08-11 Organisms homozygous for targeted modification
US13/066,636 Abandoned US20110247089A1 (en) 2009-08-11 2011-04-20 Organisms homozygous for targeted modification
US13/828,218 Abandoned US20130198878A1 (en) 2009-08-11 2013-03-14 Organisms homozygous for targeted modification
US15/990,176 Active US10827731B2 (en) 2009-08-11 2018-05-25 Method of inactivating the IPK1 gene in corn

Family Applications After (3)

Application Number Title Priority Date Filing Date
US13/066,636 Abandoned US20110247089A1 (en) 2009-08-11 2011-04-20 Organisms homozygous for targeted modification
US13/828,218 Abandoned US20130198878A1 (en) 2009-08-11 2013-03-14 Organisms homozygous for targeted modification
US15/990,176 Active US10827731B2 (en) 2009-08-11 2018-05-25 Method of inactivating the IPK1 gene in corn

Country Status (14)

Country Link
US (4) US20110041195A1 (zh)
EP (3) EP2464750A4 (zh)
JP (1) JP5940977B2 (zh)
KR (3) KR20120038020A (zh)
CN (2) CN102612565B (zh)
AR (1) AR077809A1 (zh)
AU (1) AU2010282958B2 (zh)
BR (1) BR112012003257A2 (zh)
CA (2) CA2770312A1 (zh)
HK (1) HK1212386A1 (zh)
IL (1) IL217978A (zh)
NZ (2) NZ619886A (zh)
WO (1) WO2011019385A1 (zh)
ZA (1) ZA201201008B (zh)

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110145940A1 (en) * 2009-12-10 2011-06-16 Voytas Daniel F Tal effector-mediated dna modification
US8420782B2 (en) 2009-01-12 2013-04-16 Ulla Bonas Modular DNA-binding domains and methods of use
US8470973B2 (en) 2009-01-12 2013-06-25 Ulla Bonas Modular DNA-binding domains and methods of use
US8586526B2 (en) 2010-05-17 2013-11-19 Sangamo Biosciences, Inc. DNA-binding proteins and uses thereof
WO2014011901A2 (en) 2012-07-11 2014-01-16 Sangamo Biosciences, Inc. Methods and compositions for delivery of biologics
WO2014011237A1 (en) 2012-07-11 2014-01-16 Sangamo Biosciences, Inc. Methods and compositions for the treatment of lysosomal storage diseases
WO2014036219A2 (en) 2012-08-29 2014-03-06 Sangamo Biosciences, Inc. Methods and compositions for treatment of a genetic condition
WO2014039692A2 (en) 2012-09-07 2014-03-13 Dow Agrosciences Llc Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
CN104012741A (zh) * 2013-12-20 2014-09-03 昆山御广峰机械有限公司 一种新型的棉花糖机
WO2014165612A2 (en) 2013-04-05 2014-10-09 Dow Agrosciences Llc Methods and compositions for integration of an exogenous sequence within the genome of plants
WO2015117081A2 (en) 2014-02-03 2015-08-06 Sangamo Biosciences, Inc. Methods and compositions for treatment of a beta thalessemia
US9150847B2 (en) 2011-09-21 2015-10-06 Sangamo Biosciences, Inc. Methods and compositions for regulation of transgene expression
US9260752B1 (en) 2013-03-14 2016-02-16 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US9885026B2 (en) 2011-12-30 2018-02-06 Caribou Biosciences, Inc. Modified cascade ribonucleoproteins and uses thereof
US9909131B2 (en) 2013-11-04 2018-03-06 Dow Agrosciences Llc Optimal soybean loci
WO2018073237A1 (en) 2016-10-17 2018-04-26 The University Court Of The University Of Edinburgh Swine comprising modified cd163 and associated methods
US10093940B2 (en) 2013-11-04 2018-10-09 Dow Agrosciences Llc Optimal maize loci
US10113162B2 (en) 2013-03-15 2018-10-30 Cellectis Modifying soybean oil composition through targeted knockout of the FAD2-1A/1B genes
EP3406715A1 (en) 2012-09-07 2018-11-28 Dow AgroSciences LLC Fad3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
US10227610B2 (en) 2013-02-25 2019-03-12 Sangamo Therapeutics, Inc. Methods and compositions for enhancing nuclease-mediated gene disruption
US10233465B2 (en) 2013-11-04 2019-03-19 Dow Agrosciences Llc Optimal soybean loci
US10273493B2 (en) 2013-11-04 2019-04-30 Dow Agrosciences Llc Optimal maize loci
US10301637B2 (en) 2014-06-20 2019-05-28 Cellectis Potatoes with reduced granule-bound starch synthase
US10513698B2 (en) 2012-12-21 2019-12-24 Cellectis Potatoes with reduced cold-induced sweetening
US10550402B2 (en) 2016-02-02 2020-02-04 Cellectis Modifying soybean oil composition through targeted knockout of the FAD3A/B/C genes
US10648001B2 (en) 2012-07-11 2020-05-12 Sangamo Therapeutics, Inc. Method of treating mucopolysaccharidosis type I or II
GB202007577D0 (en) 2020-05-21 2020-07-08 Oxford Genetics Ltd Hdr enhancers
GB202007578D0 (en) 2020-05-21 2020-07-08 Univ Oxford Innovation Ltd Hdr enhancers
US10837024B2 (en) 2015-09-17 2020-11-17 Cellectis Modifying messenger RNA stability in plant transformations
WO2021234389A1 (en) 2020-05-21 2021-11-25 Oxford Genetics Limited Hdr enhancers
WO2021234388A1 (en) 2020-05-21 2021-11-25 Oxford Genetics Limited Hdr enhancers
GB202118058D0 (en) 2021-12-14 2022-01-26 Univ Warwick Methods to increase yields in crops
US11312972B2 (en) 2016-11-16 2022-04-26 Cellectis Methods for altering amino acid content in plants through frameshift mutations
US11384360B2 (en) 2012-06-19 2022-07-12 Regents Of The University Of Minnesota Gene targeting in plants using DNA viruses
WO2022185312A1 (en) * 2021-03-02 2022-09-09 Betterseeds Ltd Domestication and improvement of cocoa plant
US11479782B2 (en) 2017-04-25 2022-10-25 Cellectis Alfalfa with reduced lignin composition
US11555198B2 (en) 2012-11-01 2023-01-17 Cellectis Sa Method for making nicotiana plants with mutations in XylT and FucT alleles using rare-cutting endonucleases
WO2024003579A1 (en) 2022-06-30 2024-01-04 University Of Newcastle Upon Tyne Preventing disease recurrence in mitochondrial replacement therapy

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012020257A8 (pt) * 2010-02-11 2018-02-14 Recombinetics Inc métodos e aparelhos para produzir artiodátilos transgênicos
US10920242B2 (en) 2011-02-25 2021-02-16 Recombinetics, Inc. Non-meiotic allele introgression
US9528124B2 (en) 2013-08-27 2016-12-27 Recombinetics, Inc. Efficient non-meiotic allele introgression
WO2012116274A2 (en) * 2011-02-25 2012-08-30 Recombinetics, Inc. Genetically modified animals and methods for making the same
WO2013012674A1 (en) 2011-07-15 2013-01-24 The General Hospital Corporation Methods of transcription activator like effector assembly
AU2013204327B2 (en) 2012-04-20 2016-09-01 Aviagen Cell transfection method
US9890364B2 (en) 2012-05-29 2018-02-13 The General Hospital Corporation TAL-Tet1 fusion proteins and methods of use thereof
AR091482A1 (es) * 2012-06-21 2015-02-04 Recombinetics Inc Celulas modificadas geneticamente y metodos par su obtencion
CN105188767A (zh) * 2012-07-25 2015-12-23 布罗德研究所有限公司 可诱导的dna结合蛋白和基因组干扰工具及其应用
US10058078B2 (en) * 2012-07-31 2018-08-28 Recombinetics, Inc. Production of FMDV-resistant livestock by allele substitution
EP2906602B1 (en) 2012-10-12 2019-01-16 The General Hospital Corporation Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
AU2013337951B2 (en) * 2012-10-30 2019-10-03 Recombinetics, Inc. Control of sexual maturation in animals
CN104884626A (zh) * 2012-11-20 2015-09-02 杰.尔.辛普洛公司 Tal介导的转移dna插入
WO2014124284A1 (en) 2013-02-07 2014-08-14 The General Hospital Corporation Tale transcriptional activators
CA2906970C (en) * 2013-03-21 2021-05-18 Ospedale San Raffaele Srl Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
CN105814214A (zh) 2013-10-25 2016-07-27 家畜改良有限公司 遗传标记和其用途
WO2015148680A1 (en) * 2014-03-25 2015-10-01 Ginkgo Bioworks, Inc. Methods and genetic systems for cell engineering
US9522936B2 (en) 2014-04-24 2016-12-20 Sangamo Biosciences, Inc. Engineered transcription activator like effector (TALE) proteins
LT3221457T (lt) * 2014-11-21 2019-06-10 Regeneron Pharmaceuticals, Inc. Nukreipiančios genetinės modifikacijos būdai ir kompozicijos, naudojant suporuotas kreipiančiąsias rnr sekas
CN104922697B (zh) * 2015-05-26 2018-02-27 复旦大学附属金山医院 降低磷酸吡哆醇氧化酶治疗卵巢癌
GB201517227D0 (en) * 2015-09-29 2015-11-11 Univ Edinburgh Genetically-edited swine
AU2017285224B2 (en) * 2016-06-14 2023-05-18 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease

Citations (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356802A (en) * 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5420032A (en) * 1991-12-23 1995-05-30 Universitge Laval Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5436150A (en) * 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5464764A (en) * 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5487994A (en) * 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US5658772A (en) * 1989-12-22 1997-08-19 E. I. Du Pont De Nemours And Company Site-specific recombination of DNA in plant cells
US5789538A (en) * 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
US5925523A (en) * 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
US5968793A (en) * 1997-06-24 1999-10-19 E. I. Du Pont De Nemours And Company Specific gene activation by chimeric Gal4 transcription factors in stable transgenic plants
US6007988A (en) * 1994-08-20 1999-12-28 Medical Research Council Binding proteins for recognition of DNA
US6140081A (en) * 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6140466A (en) * 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US6242568B1 (en) * 1994-01-18 2001-06-05 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US6410248B1 (en) * 1998-01-30 2002-06-25 Massachusetts Institute Of Technology General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
US6453242B1 (en) * 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6479626B1 (en) * 1998-03-02 2002-11-12 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
US6534261B1 (en) * 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US20030232410A1 (en) * 2002-03-21 2003-12-18 Monika Liljedahl Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
US20040002092A1 (en) * 2002-03-15 2004-01-01 Sylvain Arnould Hybrid and single chain meganucleases and use thereof
US6833252B1 (en) * 1992-05-05 2004-12-21 Institut Pasteur Nucleotide sequence encoding the enzyme I-SecI and the uses thereof
US20050026157A1 (en) * 2002-09-05 2005-02-03 David Baltimore Use of chimeric nucleases to stimulate gene targeting
US20050064474A1 (en) * 2003-08-08 2005-03-24 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US20050208489A1 (en) * 2002-01-23 2005-09-22 Dana Carroll Targeted chromosomal mutagenasis using zinc finger nucleases
US20060063231A1 (en) * 2004-09-16 2006-03-23 Sangamo Biosciences, Inc. Compositions and methods for protein production
US20060153826A1 (en) * 2003-01-28 2006-07-13 Sylvain Arnould Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof
US20060188987A1 (en) * 2003-08-08 2006-08-24 Dmitry Guschin Targeted deletion of cellular DNA sequences
US20070117128A1 (en) * 2005-10-18 2007-05-24 Smith James J Rationally-designed meganucleases with altered sequence specificity and DNA-binding affinity
US20070134796A1 (en) * 2005-07-26 2007-06-14 Sangamo Biosciences, Inc. Targeted integration and expression of exogenous nucleic acid sequences
US7267979B2 (en) * 2002-07-01 2007-09-11 Pioneer Hi-Bred International, Inc. Method of controlling gene silencing using site specific recombination
US20070218528A1 (en) * 2004-02-05 2007-09-20 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US20080131962A1 (en) * 2006-05-25 2008-06-05 Sangamo Biosciences, Inc. Engineered cleavage half-domains
US20080182332A1 (en) * 2006-12-14 2008-07-31 Cai Qihua C Optimized non-canonical zinc finger proteins
US20080299581A1 (en) * 2007-05-25 2008-12-04 Lars Soegaard Nielsen Screening for expressible transfectants in a eukaryotic system
US20090068164A1 (en) * 2005-05-05 2009-03-12 The Ariz Bd Of Regents On Behald Of The Univ Of Az Sequence enabled reassembly (seer) - a novel method for visualizing specific dna sequences
US20090117617A1 (en) * 2007-10-25 2009-05-07 Sangamo Biosciences, Inc. Methods and compositions for targeted integration
US20090263900A1 (en) * 2008-04-14 2009-10-22 Sangamo Biosciences, Inc. Linear donor constructs for targeted integration
US20100003756A1 (en) * 2008-06-10 2010-01-07 Sangamo BioSciences ,Inc. Methods and compositions for generation of Bax-and Bak-deficient cell lines

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4425737A (en) * 1981-10-14 1984-01-17 Agrigenetics Research Associates Limited Methods for mutant selection in cereal crops
US5422251A (en) 1986-11-26 1995-06-06 Princeton University Triple-stranded nucleic acids
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
EP0604662B1 (en) 1992-07-07 2008-06-18 Japan Tobacco Inc. Method of transforming monocotyledon
AU704601B2 (en) 1994-01-18 1999-04-29 Scripps Research Institute, The Zinc finger protein derivatives and methods therefor
US5585245A (en) 1994-04-22 1996-12-17 California Institute Of Technology Ubiquitin-based split protein sensor
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
GB2338237B (en) 1997-02-18 2001-02-28 Actinova Ltd In vitro peptide or protein expression library
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
US6342345B1 (en) 1997-04-02 2002-01-29 The Board Of Trustees Of The Leland Stanford Junior University Detection of molecular interactions by reporter subunit complementation
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
BE1011331A6 (fr) * 1997-08-20 1999-07-06 Univ Catholique De Louvain Hal Polypeptide associe au peroxysome, sequence nucleotidique encodant ledit polypeptide et leur utilisation dans le diagnostic et/ou le traitement de maladies ou de lesions pulmonaires.
AR014491A1 (es) 1998-01-29 2001-02-28 Dow Agrosciences Llc Metodo para obtener plantas transgenicas fertiles de gossypium hirsutum.
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
US20020061512A1 (en) 2000-02-18 2002-05-23 Kim Jin-Soo Zinc finger domains and methods of identifying same
AU2001263155A1 (en) 2000-05-16 2001-11-26 Massachusetts Institute Of Technology Methods and compositions for interaction trap assays
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
WO2002068955A1 (en) * 2001-02-23 2002-09-06 Elan Pharmaceuticals, Inc. Transgenic knockouts of bace-1
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
EP1421177A4 (en) 2001-08-20 2006-06-07 Scripps Research Inst ZINC FINGER FASTENING DOMAINS FOR CNN
CN1323170C (zh) * 2001-08-28 2007-06-27 日本烟草产业株式会社 修饰高等植物基因组的方法
PT1885176T (pt) * 2005-05-27 2016-11-28 Monsanto Technology Llc Evento mon89788 de soja e métodos para a sua deteção
JP2007197848A (ja) 2006-01-24 2007-08-09 Kinsei Seishi Kk 洗浄用不織布クリーナー
US7681776B2 (en) 2006-08-01 2010-03-23 Raytheon Company Methods and apparatus for efficiently generating profiles for circuit board work/rework
WO2008093152A1 (en) * 2007-02-01 2008-08-07 Cellectis Obligate heterodimer meganucleases and uses thereof
JP2008253254A (ja) * 2007-03-14 2008-10-23 National Institutes Of Natural Sciences 高効率変異導入法
DE602008003684D1 (de) 2007-04-26 2011-01-05 Sangamo Biosciences Inc Gezielte integration in die ppp1r12c-position
CN101883863B (zh) 2007-09-27 2018-01-23 桑格摩生物科学股份有限公司 生物活性核酸酶的快速体内鉴定
DE102007056956B4 (de) 2007-11-27 2009-10-29 Moosbauer, Peter, Dipl.-Ing.(FH) Schaltung zur Regelung der Stromversorgung eines Verbrauchers und Verfahren zum Betrieb einer Schaltung
EP2206723A1 (en) 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains

Patent Citations (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464764A (en) * 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5658772A (en) * 1989-12-22 1997-08-19 E. I. Du Pont De Nemours And Company Site-specific recombination of DNA in plant cells
US5420032A (en) * 1991-12-23 1995-05-30 Universitge Laval Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5436150A (en) * 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5487994A (en) * 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US5356802A (en) * 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US6833252B1 (en) * 1992-05-05 2004-12-21 Institut Pasteur Nucleotide sequence encoding the enzyme I-SecI and the uses thereof
US6140466A (en) * 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US6242568B1 (en) * 1994-01-18 2001-06-05 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US6007988A (en) * 1994-08-20 1999-12-28 Medical Research Council Binding proteins for recognition of DNA
US6013453A (en) * 1994-08-20 2000-01-11 Medical Research Council Binding proteins for recognition of DNA
US5789538A (en) * 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
US5925523A (en) * 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
US6200759B1 (en) * 1996-08-23 2001-03-13 President And Fellows Of Harvard College Interaction trap assay, reagents and uses thereof
US5968793A (en) * 1997-06-24 1999-10-19 E. I. Du Pont De Nemours And Company Specific gene activation by chimeric Gal4 transcription factors in stable transgenic plants
US6410248B1 (en) * 1998-01-30 2002-06-25 Massachusetts Institute Of Technology General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
US6479626B1 (en) * 1998-03-02 2002-11-12 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
US6903185B2 (en) * 1998-03-02 2005-06-07 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
US7153949B2 (en) * 1998-03-02 2006-12-26 Massachusetts Institute Of Technology Nucleic acid encoding poly-zinc finger proteins with improved linkers
US6140081A (en) * 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6453242B1 (en) * 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) * 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US20050208489A1 (en) * 2002-01-23 2005-09-22 Dana Carroll Targeted chromosomal mutagenasis using zinc finger nucleases
US20040002092A1 (en) * 2002-03-15 2004-01-01 Sylvain Arnould Hybrid and single chain meganucleases and use thereof
US20060078552A1 (en) * 2002-03-15 2006-04-13 Sylvain Arnould Hybrid and single chain meganucleases and use thereof
US20030232410A1 (en) * 2002-03-21 2003-12-18 Monika Liljedahl Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
US7267979B2 (en) * 2002-07-01 2007-09-11 Pioneer Hi-Bred International, Inc. Method of controlling gene silencing using site specific recombination
US20050026157A1 (en) * 2002-09-05 2005-02-03 David Baltimore Use of chimeric nucleases to stimulate gene targeting
US20060206949A1 (en) * 2003-01-28 2006-09-14 Sylvain Arnould Custom-made meganuclease and use thereof
US20060153826A1 (en) * 2003-01-28 2006-07-13 Sylvain Arnould Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof
US20060188987A1 (en) * 2003-08-08 2006-08-24 Dmitry Guschin Targeted deletion of cellular DNA sequences
US20050064474A1 (en) * 2003-08-08 2005-03-24 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US20070218528A1 (en) * 2004-02-05 2007-09-20 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US20060063231A1 (en) * 2004-09-16 2006-03-23 Sangamo Biosciences, Inc. Compositions and methods for protein production
US20090068164A1 (en) * 2005-05-05 2009-03-12 The Ariz Bd Of Regents On Behald Of The Univ Of Az Sequence enabled reassembly (seer) - a novel method for visualizing specific dna sequences
US20070134796A1 (en) * 2005-07-26 2007-06-14 Sangamo Biosciences, Inc. Targeted integration and expression of exogenous nucleic acid sequences
US20070117128A1 (en) * 2005-10-18 2007-05-24 Smith James J Rationally-designed meganucleases with altered sequence specificity and DNA-binding affinity
US20080131962A1 (en) * 2006-05-25 2008-06-05 Sangamo Biosciences, Inc. Engineered cleavage half-domains
US20080182332A1 (en) * 2006-12-14 2008-07-31 Cai Qihua C Optimized non-canonical zinc finger proteins
US20090111188A1 (en) * 2006-12-14 2009-04-30 Dow Agrosciences Llc Optimized non-canonical zinc finger proteins
US20080299581A1 (en) * 2007-05-25 2008-12-04 Lars Soegaard Nielsen Screening for expressible transfectants in a eukaryotic system
US20090117617A1 (en) * 2007-10-25 2009-05-07 Sangamo Biosciences, Inc. Methods and compositions for targeted integration
US20090263900A1 (en) * 2008-04-14 2009-10-22 Sangamo Biosciences, Inc. Linear donor constructs for targeted integration
US20100003756A1 (en) * 2008-06-10 2010-01-07 Sangamo BioSciences ,Inc. Methods and compositions for generation of Bax-and Bak-deficient cell lines

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
Chen (2002) Increased insulin and leptin sensitivity in mice lacking acyl CoA:diacylglycerol acyltransferase J. Clin. Invest. 109:1049-1055) *
Cooley (Plant Mol. Biol. 1998, Vol. 38, pg 521-530). *
Deutsch (Nucleic Acids Res. 1999, Vol. 27, No. 15, pg 3219-3228) *
Dinges (Plant Physiology, S001, Vol. 125, No. 3, pg 1406-1418 *
Koornneef (Annu. Rev. Plant Biol. 2004, Vol. 55, pg 141-172) *
Lloyd (PNAS, Feb. 8, 2005, Vol. 102, No. 6, pg 2232-2237) *
Maeder (Mol Cell. July 25, 2008, Vol. 31, Nol. 2, pg 294-301 *
map of pCAMIAB2300, 2006 *
Ramanujan (Cornell Chronicle, June 23, 2006, pg 1-2). *
Schuler (Genetics, Nov. 1954, Vol. 39, pg 908-922). *
Shen (PNAS, May 27, 2003, Vol. 100, No. 11, pg 6552-6557). *
Shukla (Nature Letters, May 21, 2009, Vol. 459, pg 437-441) *
Shukla (Nature Letters, May 21, 2009, Vol. 459, pg 437-443) *
Smith (1990) "Expression Of A Truncated Tomato Polygalacturonase Gene Inhibits Expression Of The Endogenous Gene In Transgenic Plants" Mol. Gen. Genet. vol. 224(3), pp. 477-481 *
Whitt (PNAS, Oct. 1, 2002, Vol. 99, No. 20, pg 12959-12962). *
Wright (Plant J., 2005, 44, pg 693-705 *

Cited By (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11827676B2 (en) 2009-01-12 2023-11-28 Ulla Bonas Modular DNA-binding domains and methods of use
US8420782B2 (en) 2009-01-12 2013-04-16 Ulla Bonas Modular DNA-binding domains and methods of use
US9353378B2 (en) 2009-01-12 2016-05-31 Ulla Bonas Modular DNA-binding domains and methods of use
US10590175B2 (en) 2009-01-12 2020-03-17 Ulla Bonas Modular DNA-binding domains and methods of use
US9017967B2 (en) 2009-01-12 2015-04-28 Ulla Bonas Modular DNA-binding domains and methods of use
US8470973B2 (en) 2009-01-12 2013-06-25 Ulla Bonas Modular DNA-binding domains and methods of use
US9809628B2 (en) 2009-01-12 2017-11-07 Ulla Bonas Modular DNA-binding domains and methods of use
US9453054B2 (en) 2009-01-12 2016-09-27 Ulla Bonas Modular DNA-binding domains and methods of use
US11274294B2 (en) 2009-12-10 2022-03-15 Regents Of The University Of Minnesota TAL effector-mediated DNA modification
US8440431B2 (en) 2009-12-10 2013-05-14 Regents Of The University Of Minnesota TAL effector-mediated DNA modification
US10400225B2 (en) 2009-12-10 2019-09-03 Regents Of The University Of Minnesota TAL effector-mediated DNA modification
US9758775B2 (en) * 2009-12-10 2017-09-12 Regents Of The University Of Minnesota TAL effector-mediated DNA modification
US8586363B2 (en) 2009-12-10 2013-11-19 Regents Of The University Of Minnesota TAL effector-mediated DNA modification
US8697853B2 (en) 2009-12-10 2014-04-15 Regents Of The University Of Minnesota TAL effector-mediated DNA modification
US8440432B2 (en) 2009-12-10 2013-05-14 Regents Of The University Of Minnesota Tal effector-mediated DNA modification
US20110145940A1 (en) * 2009-12-10 2011-06-16 Voytas Daniel F Tal effector-mediated dna modification
US20140335618A1 (en) * 2009-12-10 2014-11-13 Regents Of The University Of Minnesota Tal effector-mediated dna modification
US10619153B2 (en) 2009-12-10 2020-04-14 Regents Of The University Of Minnesota TAL effector-mediated DNA modification
US8450471B2 (en) 2009-12-10 2013-05-28 Regents Of The University Of Minnesota TAL effector-mediated DNA modification
US8912138B2 (en) 2010-05-17 2014-12-16 Sangamo Biosciences, Inc. DNA-binding proteins and uses thereof
US10253333B2 (en) 2010-05-17 2019-04-09 Sangamo Therapeutics, Inc. DNA-binding proteins and uses thereof
US9783827B2 (en) 2010-05-17 2017-10-10 Sangamo Therapeutics, Inc. DNA-binding proteins and uses thereof
US9322005B2 (en) 2010-05-17 2016-04-26 Sangamo Biosciences, Inc. DNA-binding proteins and uses thereof
US8586526B2 (en) 2010-05-17 2013-11-19 Sangamo Biosciences, Inc. DNA-binding proteins and uses thereof
US9493750B2 (en) 2010-05-17 2016-11-15 Sangamo Biosciences, Inc. DNA-binding proteins and uses thereof
US11661612B2 (en) 2010-05-17 2023-05-30 Sangamo Therapeutics, Inc. DNA-binding proteins and uses thereof
US11859190B2 (en) 2011-09-21 2024-01-02 Sangamo Therapeutics, Inc. Methods and compositions for regulation of transgene expression
US9394545B2 (en) 2011-09-21 2016-07-19 Sangamo Biosciences, Inc. Methods and compositions for regulation of transgene expression
EP3498833A1 (en) 2011-09-21 2019-06-19 Sangamo Therapeutics, Inc. Methods and compositions for regulation of transgene expression
US9150847B2 (en) 2011-09-21 2015-10-06 Sangamo Biosciences, Inc. Methods and compositions for regulation of transgene expression
US10975375B2 (en) 2011-09-21 2021-04-13 Sangamo Therapeutics, Inc. Methods and compositions for regulation of transgene expression
US11639504B2 (en) 2011-09-21 2023-05-02 Sangamo Therapeutics, Inc. Methods and compositions for regulation of transgene expression
US9777281B2 (en) 2011-09-21 2017-10-03 Sangamo Therapeutics, Inc. Methods and compositions for regulation of transgene expression
US10954498B2 (en) 2011-12-30 2021-03-23 Caribou Biosciences, Inc. Modified cascade ribonucleoproteins and uses thereof
US10711257B2 (en) 2011-12-30 2020-07-14 Caribou Biosciences, Inc. Modified cascade ribonucleoproteins and uses thereof
US10435678B2 (en) 2011-12-30 2019-10-08 Caribou Biosciences, Inc. Modified cascade ribonucleoproteins and uses thereof
US11939604B2 (en) 2011-12-30 2024-03-26 Caribou Biosciences, Inc. Modified cascade ribonucleoproteins and uses thereof
US9885026B2 (en) 2011-12-30 2018-02-06 Caribou Biosciences, Inc. Modified cascade ribonucleoproteins and uses thereof
US11384360B2 (en) 2012-06-19 2022-07-12 Regents Of The University Of Minnesota Gene targeting in plants using DNA viruses
US9956247B2 (en) 2012-07-11 2018-05-01 Sangamo Therapeutics, Inc. Method of treating lysosomal storage diseases
US9877988B2 (en) 2012-07-11 2018-01-30 Sangamo Therapeutics, Inc. Method of treating lysosomal storage diseases using nucleases and a transgene
US11898158B2 (en) 2012-07-11 2024-02-13 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of lysosomal storage diseases
EP3444342A1 (en) 2012-07-11 2019-02-20 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of lysosomal storage diseases
US10648001B2 (en) 2012-07-11 2020-05-12 Sangamo Therapeutics, Inc. Method of treating mucopolysaccharidosis type I or II
US10883119B2 (en) 2012-07-11 2021-01-05 Sangamo Therapeutics, Inc. Methods and compositions for delivery of biologics
WO2014011901A2 (en) 2012-07-11 2014-01-16 Sangamo Biosciences, Inc. Methods and compositions for delivery of biologics
WO2014011237A1 (en) 2012-07-11 2014-01-16 Sangamo Biosciences, Inc. Methods and compositions for the treatment of lysosomal storage diseases
EP3816281A1 (en) 2012-07-11 2021-05-05 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of lysosomal storage diseases
US10293000B2 (en) 2012-07-11 2019-05-21 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of lysosomal storage diseases
US11040115B2 (en) 2012-07-11 2021-06-22 Sangamo Therapeutics, Inc. Method for the treatment of lysosomal storage diseases
US9650648B2 (en) 2012-08-29 2017-05-16 Sangamo Biosciences, Inc. Methods and compositions for treatment of a genetic condition
WO2014036219A2 (en) 2012-08-29 2014-03-06 Sangamo Biosciences, Inc. Methods and compositions for treatment of a genetic condition
US9963715B2 (en) 2012-08-29 2018-05-08 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a genetic condition
US11492643B2 (en) 2012-08-29 2022-11-08 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a genetic condition
WO2014039702A2 (en) 2012-09-07 2014-03-13 Dow Agrosciences Llc Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
US10577616B2 (en) 2012-09-07 2020-03-03 Dow Agrosciences Llc FAD2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
US10844389B2 (en) 2012-09-07 2020-11-24 Dow Agrosciences Llc FAD2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
EP3406715A1 (en) 2012-09-07 2018-11-28 Dow AgroSciences LLC Fad3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
US10287595B2 (en) 2012-09-07 2019-05-14 Dow Agrosciences Llc Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
EP3431600A1 (en) 2012-09-07 2019-01-23 Dow AgroSciences LLC Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
US9963711B2 (en) 2012-09-07 2018-05-08 Sangamo Therapeutics, Inc. FAD2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
US9493779B2 (en) 2012-09-07 2016-11-15 Dow Agrosciences Llc FAD2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
WO2014039692A2 (en) 2012-09-07 2014-03-13 Dow Agrosciences Llc Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
EP3404099A1 (en) 2012-09-07 2018-11-21 Dow AgroSciences LLC Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
US11555198B2 (en) 2012-11-01 2023-01-17 Cellectis Sa Method for making nicotiana plants with mutations in XylT and FucT alleles using rare-cutting endonucleases
US11576317B2 (en) 2012-11-01 2023-02-14 Cellectis Sa Mutant Nicotiana benthamiana plant or cell with reduced XylT and FucT
US10513698B2 (en) 2012-12-21 2019-12-24 Cellectis Potatoes with reduced cold-induced sweetening
US10227610B2 (en) 2013-02-25 2019-03-12 Sangamo Therapeutics, Inc. Methods and compositions for enhancing nuclease-mediated gene disruption
US9260752B1 (en) 2013-03-14 2016-02-16 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US11312953B2 (en) 2013-03-14 2022-04-26 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US9410198B2 (en) 2013-03-14 2016-08-09 Caribou Biosciences, Inc. Compostions and methods of nucleic acid-targeting nucleic acids
US9909122B2 (en) 2013-03-14 2018-03-06 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US9803194B2 (en) 2013-03-14 2017-10-31 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US10125361B2 (en) 2013-03-14 2018-11-13 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US9809814B1 (en) 2013-03-14 2017-11-07 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US9725714B2 (en) 2013-03-14 2017-08-08 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US10113162B2 (en) 2013-03-15 2018-10-30 Cellectis Modifying soybean oil composition through targeted knockout of the FAD2-1A/1B genes
US10501748B2 (en) 2013-04-05 2019-12-10 Dow Agrosciences Llc Methods and compositions for integration of an exogenous sequence within the genome of plants
EP3679785A2 (en) 2013-04-05 2020-07-15 Dow AgroSciences LLC Methods and compositions for integration of an exogenous sequence within the genome of plants
WO2014165612A2 (en) 2013-04-05 2014-10-09 Dow Agrosciences Llc Methods and compositions for integration of an exogenous sequence within the genome of plants
US11198883B2 (en) 2013-04-05 2021-12-14 Dow Agrosciences Llc Methods and compositions for integration of an exogenous sequence within the genome of plants
US11198882B2 (en) 2013-11-04 2021-12-14 Corteva Agriscience Llc Optimal maize loci
US11098317B2 (en) 2013-11-04 2021-08-24 Corteva Agriscience Llc Optimal maize loci
US11149287B2 (en) 2013-11-04 2021-10-19 Corteva Agriscience Llc Optimal soybean loci
US9909131B2 (en) 2013-11-04 2018-03-06 Dow Agrosciences Llc Optimal soybean loci
US11098316B2 (en) 2013-11-04 2021-08-24 Corteva Agriscience Llc Optimal soybean loci
US10093940B2 (en) 2013-11-04 2018-10-09 Dow Agrosciences Llc Optimal maize loci
US10106804B2 (en) 2013-11-04 2018-10-23 Dow Agrosciences Llc Optimal soybean loci
US10233465B2 (en) 2013-11-04 2019-03-19 Dow Agrosciences Llc Optimal soybean loci
US10273493B2 (en) 2013-11-04 2019-04-30 Dow Agrosciences Llc Optimal maize loci
CN104012741A (zh) * 2013-12-20 2014-09-03 昆山御广峰机械有限公司 一种新型的棉花糖机
US10072066B2 (en) 2014-02-03 2018-09-11 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a beta thalessemia
WO2015117081A2 (en) 2014-02-03 2015-08-06 Sangamo Biosciences, Inc. Methods and compositions for treatment of a beta thalessemia
US10301637B2 (en) 2014-06-20 2019-05-28 Cellectis Potatoes with reduced granule-bound starch synthase
US10837024B2 (en) 2015-09-17 2020-11-17 Cellectis Modifying messenger RNA stability in plant transformations
US10550402B2 (en) 2016-02-02 2020-02-04 Cellectis Modifying soybean oil composition through targeted knockout of the FAD3A/B/C genes
WO2018073237A1 (en) 2016-10-17 2018-04-26 The University Court Of The University Of Edinburgh Swine comprising modified cd163 and associated methods
US11312972B2 (en) 2016-11-16 2022-04-26 Cellectis Methods for altering amino acid content in plants through frameshift mutations
US11479782B2 (en) 2017-04-25 2022-10-25 Cellectis Alfalfa with reduced lignin composition
GB202007577D0 (en) 2020-05-21 2020-07-08 Oxford Genetics Ltd Hdr enhancers
GB202007578D0 (en) 2020-05-21 2020-07-08 Univ Oxford Innovation Ltd Hdr enhancers
WO2021234388A1 (en) 2020-05-21 2021-11-25 Oxford Genetics Limited Hdr enhancers
WO2021234389A1 (en) 2020-05-21 2021-11-25 Oxford Genetics Limited Hdr enhancers
WO2022185312A1 (en) * 2021-03-02 2022-09-09 Betterseeds Ltd Domestication and improvement of cocoa plant
WO2023111541A1 (en) 2021-12-14 2023-06-22 The University Of Warwick Methods to increase yields in crops
GB202118058D0 (en) 2021-12-14 2022-01-26 Univ Warwick Methods to increase yields in crops
WO2024003579A1 (en) 2022-06-30 2024-01-04 University Of Newcastle Upon Tyne Preventing disease recurrence in mitochondrial replacement therapy

Also Published As

Publication number Publication date
AU2010282958A1 (en) 2012-03-01
EP3156504B1 (en) 2018-10-31
CN102612565A (zh) 2012-07-25
EP3428289A1 (en) 2019-01-16
KR20120038020A (ko) 2012-04-20
US20180263228A1 (en) 2018-09-20
NZ619886A (en) 2015-03-27
IL217978A (en) 2017-09-28
WO2011019385A1 (en) 2011-02-17
EP3156504A1 (en) 2017-04-19
US10827731B2 (en) 2020-11-10
BR112012003257A2 (pt) 2016-11-22
HK1212386A1 (zh) 2016-06-10
AR077809A1 (es) 2011-09-21
KR102262704B1 (ko) 2021-06-09
CA2770312A1 (en) 2011-02-17
JP2013501520A (ja) 2013-01-17
CA3040550A1 (en) 2011-02-17
US20110247089A1 (en) 2011-10-06
CA3040550C (en) 2021-09-21
AU2010282958B2 (en) 2015-05-21
CN102612565B (zh) 2016-04-06
JP5940977B2 (ja) 2016-06-29
KR20190136122A (ko) 2019-12-09
EP2464750A4 (en) 2013-10-02
CN104830894B (zh) 2019-03-01
KR20170125406A (ko) 2017-11-14
IL217978A0 (en) 2012-03-29
CN104830894A (zh) 2015-08-12
EP3428289B1 (en) 2020-05-20
ZA201201008B (en) 2012-10-31
US20130198878A1 (en) 2013-08-01
EP2464750A1 (en) 2012-06-20
NZ598053A (en) 2014-01-31

Similar Documents

Publication Publication Date Title
US10827731B2 (en) Method of inactivating the IPK1 gene in corn
US20220356493A1 (en) Dna-binding proteins and uses thereof
CA2901676C (en) Methods and compositions for enhancing nuclease-mediated gene disruption
US20230374529A1 (en) Reconstruction of site specific nuclease binding sites

Legal Events

Date Code Title Description
AS Assignment

Owner name: SANGAMO BIOSCIENCES, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DOYON, YANNICK;REEL/FRAME:025195/0801

Effective date: 20100913

AS Assignment

Owner name: SANGAMO THERAPEUTICS, INC., CALIFORNIA

Free format text: CHANGE OF NAME;ASSIGNOR:SANGAMO BIOSCIENCES, INC.;REEL/FRAME:046246/0067

Effective date: 20170105

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION